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 ABSTRACT: We have synthesized a family of rhein–huprine hybrids to hit several key targets 
for Alzheimer’s disease. Biological screening performed in vitro and in Escherichia coli cells has 
shown that these hybrids exhibit potent inhibitory activities against human acetylcholinesterase 
butyrylcholinesterase, and BACE-1, dual Aβ42 and tau anti-aggregating activity, and brain 
permeability. Ex vivo studies with the leads (+)- and (–)-7e in brain slices of C57bl6 mice have 
revealed that they efficiently protect against the Aβ-induced synaptic dysfunction , preventing 
the loss of synaptic proteins and/or have a positive effect on the induction of long term 
potentiation. In vivo studies in APP-PS1 transgenic mice treated i.p. for 4 weeks with (+)- and (–
)-7e have shown a central soluble Aβ lowering effect, accompanied by an increase in the levels 
of mature amyloid precursor protein (APP). Thus, (+)- and (–)-7e emerge as very promising 
disease-modifying anti-Alzheimer drug candidates. 
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INTRODUCTION 
Alzheimer’s disease (AD), the most common type of dementia, is associated with ever 
increasing unacceptable personal and economic costs, owing to its high prevalence, mortality 
and, worryingly, to the elusiveness of efficacious drugs.1 
There has been a general consensus that β-amyloid peptide (Aβ) is the main culprit of a 
straightforward cascade process that begins with its increased formation by processing of the 
amyloid precursor protein (APP) by β-secretase (BACE-1) and γ-secretase, and aggregation into 
oligomers and fibrils. This follows with a series of downstream events including synaptic 
dysfunction, tau protein hyperphosphorylation and aggregation, neuroinflammation and 
oxidative stress, and eventually leads to neuronal death and neurotransmitter deficits.2,3 Because 
these deficits account for the cognitive and functional decline, which are the main diagnostic 
criteria for AD, the first and so far the sole marketed anti-Alzheimer drugs, namely the 
acetylcholinesterase (AChE) inhibitors tacrine, donepezil, rivastigmine and galantamine and the 
NMDA receptor antagonist memantine, were developed to hit those neurotransmitter deficits, 
particularly cholinergic and glutamatergic, but are regarded as merely symptomatic.  
In the past years, there has been an intense research activity for developing drugs able to tackle 
the underlying mechanism of AD, by hitting Aβ formation or aggregation or, to a minor extent, 
other downstream targets.4 However, despite the acute need and the hopes raised for the 
discovery of effective disease-modifying anti-Alzheimer drugs, a number of clinically advanced 
Aβ-directed drug candidates have recently failed to show efficacy over placebo or they have 
been discontinued because of their toxicity. The efficacy issues of these drug candidates have 
been ascribed, at least partly, to the fact that AD pathology might not result from a 
straightforward process, but from a robust network of interconnected events, whereby Aβ 
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aggregation is not the cause but just one of the causes, together with tau hyperphosphorylation 
and aggregation, synaptic dysfunction or neuroinflammation.5 This novel conception of AD 
would allow explaining why modulation of a single target might be ineffective, whereas 
simultaneous modulation of several targets of the network, including Aβ, holds promise for 
deriving the eagerly awaited effective disease-modifying anti-Alzheimer drugs.6–10 
In the past years, many research groups have pursued the development of multi-target anti-
Alzheimer drugs as an advantageous approach over multi-target multi-drug strategies (drug 
cocktails and fixed-dose combinations).11–15 Multi-target compounds have been usually designed 
to hit at least Aβ formation and aggregation and AChE activity,16 especially prompted by the 
finding that AChE can bind Aβ, thereby promoting its aggregation and increasing its 
neurotoxicity.17–19 The recognition site of Aβ within AChE is the so-called peripheral anionic site 
(PAS) and it is located at the entrance of a 20 Å deep narrow gorge that leads to the catalytic 
anionic site (CAS).20 The design of inhibitors able to simultaneously reach both sites of AChE, 
i.e. dual binding site AChE inhibitors (AChEIs), emerged some years ago as a promising source 
of multi-target anti-Alzheimer compounds, inasmuch as they should be endowed at least with 
potent anticholinesterase and Aβ anti-aggregating effects.21–29 Moreover, the multi-target profile 
of these compounds can be enlarged by introducing pharmacophoric moieties that are also 
suitable for separate interactions with additional targets of interest other than AChE and Aβ. Two 
major challenges in the design and therapeutic potential of multi-target anti-Alzheimer agents are 
the choice of the targets to be hit and the potency of the compounds at the different targets. 
Indeed, it must be recognized that the timing of the different events in the progression of AD can 
be overlooked when selecting the biological targets to be hit. However, this issue will remain 
very difficult to be addressed until a precise description of the sequence of events that give rise 
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to the neuropathogenesis of AD becomes available. On the other hand, a multi-target action will 
be only effective when balanced activities are achieved at the different targets, which is also not 
an easy task. 
Recently, the hydroxyanthraquinone derivatives emodin, 1, and PHF016, 2 (Chart 1), have 
been shown to inhibit tau aggregation in vitro with IC50 values in the low micromolar range.30,31 
The structurally related compound rhein, 3 (Chart 1) is a natural product found in the traditional 
Chinese herbal medicine rhubarb, which is well tolerated in humans.32 In the form of a doubly 
acetylated prodrug, diacerein, it is used for the treatment of arthritis. Even though rhein has been 
reported to be essentially inactive as inhibitor of AChE33,34 and of Aβ aggregation,35 its aromatic 
rings seem appropriate for establishing π-stacking interactions with the characteristic aromatic 
residue at the PAS of AChE, namely Trp286 (human AChE (hAChE) numbering). Moreover, its 
hydroxyanthraquinone scaffold might confer tau anti-aggregating properties to its derivatives. 
Thus, we inferred that combination in a hybrid of the hydroxyanthraquinone system of rhein with 
a moiety with high affinity for the CAS of AChE might result in a multi-target compound of 
interest for the treatment of AD, which should be endowed at least with AChE, Aβ aggregation 
and tau aggregation inhibitory activities. 
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Chart 1. Structures of tau aggregation inhibitors 1 and 2, rhein and huprine Y 
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Herein, we describe the synthesis, biological profiling, and investigation of the mechanism of 
action of a novel family of multi-target hybrid compounds, which are composed of a unit of 
rhein attached, through different linkers, to a unit of huprine Y, 4 (Chart 1), a high affinity 
AChE’s CAS inhibitor, developed in our group some years ago.36–39 The biological profiling 
includes i) the in vitro evaluation of the inhibitory activities against hAChE, human 
butyrylcholinesterase (hBChE), hAChE-induced and self-induced Aβ aggregation, and human 
BACE-1 (hBACE-1), ii) the evaluation of the Aβ and tau anti-aggregating activities in intact 
Escherichia coli cells overexpressing these peptides, iii) the evaluation of the protective effects 
on synaptic integrity from Aβ-induced alterations by measuring the induction of long term 
potentiation and levels of synaptic proteins in hippocampal slices of 2-month-old C57bl6 mice, 
and iv) the assessment of their brain permeability using an artificial membrane model. 
Furthermore, kinetic and molecular modeling studies have been performed to shed light on the 
binding mode of these compounds with two of their main targets, namely AChE and BACE-1. 
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RESULTS AND DISCUSSION 
Chemistry. The linkage between the huprine and rhein moieties was envisioned at one end 
through an N–C bond from the exocyclic amino group of huprine Y, as in a recently reported 
family of huprine-based dual binding site AChEI hybrids,40 and at the other end through an 
amide bond from the carboxylic acid of rhein. Such linkages have proven to be chemically stable 
at physiological pH up to 4 days at 37 ºC in a structurally related family of hybrid compounds.41 
Chains from 5 to 11 methylene groups were considered for the linkers (in hybrids 7a–g, Scheme 
1), to afford suitable distances between huprine and rhein moieties to achieve a dual site binding 
to AChE and to explore the effect of the length of the linker in a target with a large binding site 
such as BACE-1. The incorporation of an aromatic ring within the linker, i.e. a 1,4-phenylene-
bis(methylene) linker (in hybrid 7h, Scheme 1), was also envisaged to explore potential 
additional interactions with the targets, i.e. interactions with midgorge residues of AChE or 
disruption of protein–protein interactions in the case of Aβ and tau aggregation. 
Rhein–huprine hybrids 7a–h were synthesized through a three- or four-step sequence from 
readily available racemic or enantiopure huprine Y, (±)-, (–)- or (+)-4,36–38 and commercial rhein, 
3 (Scheme 1). Alkylation of racemic huprine Y with commercial or described ω-
bromoalkanenitriles42–44 in the presence of KOH in DMSO afforded nitriles (±)-5a–g in 
moderate yields (25–87%). Nitrile (±)-5h was prepared in 72% overall yield by condensation of 
racemic huprine with 4-cyanobenzaldehyde followed by NaBH3CN reduction of the resulting 
imine. LiAlH4 reduction of nitriles (±)-5a–h gave in excellent yields amines (±)-6a–h, which 
were reacted with the mixed anhydride formed from rhein and ethyl chloroformate to afford in 
9–27% yield the rhein–huprine hybrids (±)-7a–h. 
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Scheme 1. Synthesis of the rhein–huprine hybrids 7a–h 
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In the light of the biological results obtained for the racemic hybrids 7a–h, we decided to 
synthesize the two enantiomers of the most interesting racemic hybrid, namely 7e. Thus, 
enantiopure (–)- and (+)-7e were prepared from (–)- and (+)-4 (>99% ee) using the same 
methodology. 
The novel rhein–huprine hybrids were fully characterized in the form of hydrochloride salts 
through their spectroscopic data (IR, 1H and 13C NMR), HRMS and elemental analysis. 
Hydrochloride salts were also used for the activity profile assessment. 
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In Vitro Biological Profiling of Racemic Rhein–Huprine Hybrids. Inhibition of human 
cholinesterases and molecular modeling study of hAChE inhibition. Apart from AChE, BChE is 
another target of interest in the search for anti-Alzheimer drugs, inasmuch as this enzyme exerts 
a compensatory effect in response to a greatly decreased AChE activity in central nervous system 
(CNS) when AD progresses.45 Accordingly, the inhibitory activity of the novel rhein–huprine 
hybrids and of the reference compounds rhein and huprine Y against human recombinant AChE 
(hAChE) and human serum BChE (hBChE) was evaluated by the method of Ellman et al.46  
All the racemic hybrids, (±)-7a–h, turned out to be potent inhibitors of hAChE, with IC50 
values in the low nanomolar range (Table 1), even though both the length of the linker and the 
presence of an aromatic ring in the linker seemed to have only a moderate effect on the hAChE 
inhibitory activity. Indeed, the inhibitory potency gradually decreased from the shortest 
pentamethylene-linked hybrid (±)-7a to the longest undecamethylene homologue, (±)-7g (16-
fold less potent), whereas introduction of an aromatic ring within the linker seemed to be 
detrimental for hAChE inhibitory activity, hybrid (±)-7h being 12-fold less potent than hybrid 
(±)-7b with a similar tether length. Hybrid (±)-7a, the most potent hAChEI of the series (IC50 
1.07 nM), was equipotent to the parent racemic huprine Y [(±)-4]. In agreement with the reported 
data,33,34 the parent rhein, 3, was found essentially inactive against hAChE.  
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Table 1. Inhibitory Activities of the Hydrochlorides of RheinHuprine Hybrids and 
Reference Compounds toward AChE, BChE, BACE-1, and AChE-Induced and Self-
Induced Aβ Aggregation and BBB Predicted Permeabilitiesa 
compd hAChE 
IC50 (nM)b 
hBChE 
IC50 (nM)b 
hBACE-1 
IC50 (nM)b 
hAChE-
induced Aβ40 
aggregation  
(% inhib.)c 
self-induced 
Aβ42  
aggregation 
(% inhib.)d 
Pe (106 cm s1)e 
(Prediction) 
(±)-7a 1.07 ± 0.05 950 ± 30 naf 45.0 ± 7.5 38.7 ± 5.0 20.0 ± 1.0 (CNS+) 
(±)-7b 1.52 ± 0.08 1070 ± 40 naf 50.5 ± 8.7 40.8 ± 5.7 ndg 
(±)-7c 3.18 ± 0.16 1460 ± 160 naf 52.5 ± 2.9 40.6 ± 1.9 27.5 ± 0.7 (CNS+) 
(±)-7d 4.36 ± 0.22 350 ± 20 980 ± 170 44.7 ± 8.4 33.1 ± 5.4 22.4 ± 1.3 (CNS+) 
(±)-7e 3.60 ± 0.21 620 ± 20 120 ± 90 48.7 ± 8.4 38.0 ± 4.6 21.5 ± 0.7 (CNS+) 
(+)-7e 2930 ± 285 265 ± 21 80 ± 10 36.9 ± 3.4 38.4 ± 5.5 ndg 
(–)-7e 2.39 ± 0.17 513 ± 58 80 ± 10 38.1 ± 0.7 43.2 ± 4.7 ndg 
(±)-7f 7.61 ± 0.45 1100 ± 40 1190 ± 180 29.2 ± 2.4 40.9 ± 4.4 18.1 ± 0.7 (CNS+) 
(±)-7g 17.4 ± 2.2 645 ± 67 1200 ± 150 38.2 ± 2.6 35.3 ± 4.0 16.4 ± 1.0 (CNS+) 
(±)-7h 18.2 ± 2.2 510 ± 20 2020 ± 440 35.2 ± 1.8 32.4 ± 3.6 16.3 ± 2.5 (CNS+) 
3 >10000 17000 ± 4220 nah ndg ndg 2.7 ± 0.1 (CNS+/–) 
(±)-4 1.07 ± 0.05 181 ± 15 ndg 17.1 ± 4.5 ndg 23.8 ± 2.7 (CNS+) 
(+)-4 321 ± 16 170 ± 17 >5000i 9.1 ± 3.6 13.2 ± 1.9 25.4 ± 2.9 (CNS+) 
(–)-4 0.74 ± 0.06 222 ± 17 >5000j 24.7 ± 1.3 11.5 ± 5.2 23.6 ± 1.1 (CNS+) 
a Values are expressed as mean ± standard error of the mean (SEM) of at least three 
experiments (n=3), each performed in duplicate. b IC50 inhibitory concentration (nM) of human 
recombinant AChE, human serum BChE, or human recombinant BACE-1. c % inhibition with 
inhibitor at 100 μM, Aβ40 at 230 μM and hAChE at 2.3 μM. d % inhibition with inhibitor at 10 
μM and Aβ42 at 50 μM ([A]/[I]=5/1). e Permeability values from the PAMPA-BBB assay. f Not 
active at 1 μM. g Not determined. h Not active. i 13.6 ± 2.3% inhibition at 5 μM. j 14.0 ± 0.1% 
inhibition at 5 μM. 
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The binding mode of the rhein–huprine hybrids to AChE was explored for compound 7h, 
taking advantage of the reduced flexibility imposed by the aromatic ring. Docking studies 
showed that (–)-7h binds much more favorably than (+)-7h, as expected from the fact that the 
eutomer of huprines for AChE inhibition is the levorotatory (7S,11S)-enantiomer, (–)-4. The 
results show that (–)-7h may fit the hAChE gorge (Figure 1) placing i) the huprine moiety in an 
orientation that perfectly matches the arrangement of (–)-huprine X, the 9-ethyl-analog of (–)-
huprine Y, in the CAS (PDB entry 1E66, Figure S1), and ii) the hydroxyanthraquinone system of 
rhein stacked between the aromatic rings of Trp286 and Tyr72 in the PAS, mimicking the 
arrangement of the tacrine unit of bis(7)-tacrine (PDB entry 2CKM, Figure S2).47 Even though 
these findings support the ability of the hybrids to interact simultaneously at both CAS and PAS, 
the inhibitory potencies in Table 1 suggest that the rhein unit has a weak contribution to the 
binding, presumably due to the lack of a positive charge that would reinforce the stacking 
interaction, as compared with the inhibitory potency of bis(7)-tacrine (IC50 hAChE 0.81 nM)48 
and huprine–tacrine hybrids (IC50 hAChE up to 0.31 nM),40 and to the lack of specific 
interactions formed by the polar groups of the hydroxyanthraquinone moiety at the PAS, thereby 
preventing a net gain in potency compared to huprine Y, (±)-4. 
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 Figure 1. Binding mode of compound (–)-7h (shown as yellow sticks) in the AChE gorge. 
 
All the rhein–huprine hybrids turned out to be selective for hAChE over hBChE inhibition, 
with selectivities in the range 28–888. However, these hybrids still exhibited a moderately potent 
hBChE inhibitory activity, with IC50 values in the submicromolar to low micromolar range 
(Table 1). The most potent hBChE inhibitor of the series, (±)-7d (IC50 = 350 nM), was slightly 
less potent than the parent huprine (2-fold) but 50-fold more potent than the parent rhein, 3. 
Inhibition of AChE-induced Aβ aggregation. The occupancy of the AChE’s PAS by the rhein–
huprine hybrids, predicted by docking simulations (see above), should result in a hindrance of 
the interaction of Aβ with AChE, and, hence, in a blockade of the Aβ proaggregating action of 
the enzyme. The inhibitory activity of these hybrids and the parent rhein and huprine Y against 
the AChE-induced aggregation of Aβ40 was assessed using a thioflavin T-based fluorescent 
method.49 Rhein–huprine hybrids exhibited a significant inhibitory activity against the AChE-
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induced Aβ40 aggregation, exhibiting percentages of inhibition ranging from 29 to 52% at a 100 
μM concentration, which are clearly superior to that found for the AChE’s CAS inhibitor huprine 
Y, 4 (Table 1). These activities are similar to those reported for other families of dual binding 
site AChEIs,40,50–55 even though more potent inhibitors of the AChE-induced Aβ40 aggregation 
have been described.56,57 In agreement with the hypothesis that both inhibitory activities are 
related to some extent to the ability of interacting with the AChE’s PAS, the inhibitory activities 
of the rhein–huprine hybrids against the AChE-induced Aβ40 aggregation roughly matches the 
SAR trends for hAChE inhibition, i.e. the shorter homologues are the most potent and the 
presence of a benzene ring in the linker is slightly detrimental for the activity. 
Inhibition of self-induced Aβ aggregation. The inhibitory activity of the rhein–huprine hybrids 
against the spontaneous aggregation of Aβ42 was determined in vitro using a thioflavin T-based 
fluorometric assay.58 These compounds exhibit a significant Aβ42 anti-aggregating activity, 
displaying percentages of inhibition in the narrow range 32-41% when tested at a concentration 
equal to 1/5 of that of Aβ42 ([I] = 10 μM, [Aβ42] = 50 μM), they being clearly more potent than 
the parent huprine Y (Table 1). Of note, rhein could not be evaluated because of solubility 
problems under the assay conditions. 
Inhibition of human BACE-1 and molecular modeling study. BACE-1 catalyzes the first and 
rate-limiting step of the biosynthesis of Aβ from APP, thereby constituting a prime target in the 
search for disease-modifying anti-Alzheimer drugs.59,60 Strikingly, a number of dual binding site 
AChEIs have been found to be potent or moderately potent inhibitors of BACE-1, even if they 
were not purported to display this activity.61 In most cases, these compounds inhibit BACE-1 
with low micromolar IC50 values, as it happens with the prototypic dual binding site AChEI 
bis(7)-tacrine (IC50 7.5 μM)62 or with huprine–tacrine heterodimers (IC50 4.9–7.3 μM).40 
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However, another dual binding site AChEI with more potent BACE-1 inhibitory activity, i.e. 
memoquin (IC50 108 nM),56 has also been reported. 
In the light of these results, the novel racemic rhein–huprine hybrids were tested in vitro 
against human recombinant BACE-1 using a FRET assay.63 Results clearly showed the 
importance of the linker chain length. The pentamethylene- to heptamethylene-linked hybrids 
(±)-7a–c were inactive for BACE-1 inhibition at a concentration of 1 μM, whereas the longer 
homologues (±)-7d, (±)-7f, and (±)-7g, as well as (±)-7h, containing an aromatic ring in the 
linker, exhibited a moderately potent BACE-1 inhibitory activity, with IC50 values around 1–2 
μM (Table 1). Far beyond our expectations, the BACE-1 inhibitory activity in this series peaked 
for the nonamethylene-linked hybrid (±)-7e, with a remarkable IC50 value of 120 nM. Thus, (±)-
7e was roughly equipotent to memoquin,56 about 50-fold more potent than bis(7)-tacrine62 and 
other huprine-based hybrids.40 Very interestingly, the BACE-1 inhibitory activity of (±)-7e 
seems to be slightly higher than that of the Lilly’s BACE-1 inhibitor LY2811376, a very 
promising anti-Alzheimer drug candidate whose Phase I clinical trials were recently discontinued 
due to toxicity issues unrelated to BACE-1 inhibition,59 even though a head-to-head test in the 
same assay conditions would be required to confirm that point. Thus, the combination of huprine 
Y and rhein in a new hybrid molecule with a proper linker chain led to a significant enlargement 
of the activity profile, namely the strong inhibitory activity on BACE-1 that is not present in any 
of the parent compounds. 
The preceding findings made it worth to determine the binding mode of the hybrids to BACE-
1. In a first step, this was accomplished by examining the druggable pockets present in the 
enzyme in order to determine their ability to accommodate the huprine and 
hydroxyanthraquinone moities (see Experimental Section). Among the seven druggable pockets 
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shared by the four X-ray structures explored with the MDpocket program (PDB entries 1M4H, 
1SGZ, 2OHL and 3CIB), only two of them, namely BS1, which encompasses the catalytic site, 
and BS2, which includes subsites P5–P7 (Figure S3, Supporting Information), were found to be 
suitable for binding of the huprine and hydroxyanthraquinone moieties present in hybrids. 
Furthermore, the distance between the centroids of the most populated clusters of huprine and 
hydroxyanthraquinone in these pockets was comprised between 7 and 11 Å, thus satisfying the 
geometrical criteria required for the tether in the rhein–huprine hybrids. Accordingly, docking of 
(+)-7h and (–)-7h was performed by exploring the volume defined by both BS1 and BS2 sites. 
Even though this compound is not the most potent within the series, it was chosen due to the 
limited number of rotatable bonds, which thus makes it easier to perform a more exhaustive 
exploration of the binding mode and examine the potential interaction at the two pockets 
identified separately for huprine and hydroxyanthraquinone moieties. Calculations led to a clear 
binding mode, in which the huprine moiety is accommodated at the BS1 pocket, and the 
hydroxyanthraquinone moiety fills the BS2 site. The structural integrity of this binding mode 
was supported by the analysis of four independent 50 ns molecular dynamics simulations run for 
both (+)-7h and (–)-7h bound to the enzyme (Figure 2). The huprine moiety remains tightly 
bound to BS1 in all cases, as expected from the electrostatic stabilization between the protonated 
aminoquinoline system and the catalytic dyad (Asp32 and Asp228), whereas the bicyclic system 
of the huprine moiety fills the hydrophobic pocket formed by residues Leu30, Phe108, Ile110 
and Ile118 from subsites P2 and P3. On the other hand, the hydroxyanthraquinone moiety in (+)-
7h exhibits a common binding mode, which involves the electrostatic interaction with Lys321, 
hydrogen bonds with the backbone of Phe322 and the side chain of Asn233, and hydrophobic 
contacts with Val309. For (–)-7h, the results show that, besides the preceding binding mode, the 
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hydroxyanthraquinone moiety can adopt an alternative arrangement, which mainly involves the 
direct electrostatic interaction with Arg307. On the basis of these findings, it is reasonable to 
expect that the larger flexibility afforded by the linker in 7e will facilitate a proper 
accommodation to both BS1 and BS2 in BACE-1, thus explaining the increase in BACE-1 
inhibitory activity compared to 7h. Overall, this analysis suggests that BS2 may be exploited to 
find novel moieties leading to enhanced binding affinity and hence to hybrid compounds with 
more potent inhibitory activity against BACE-1. 
 
 
Figure 2. Superposition of the last snapshots sampled in four independent MD simulations of  
hybrid compounds (A) (+)-7h (shown as orange sticks) and (B) (–)-7h (shown as yellow sticks) 
bound to BACE-1 (shown as cyan cartoon). Selected residues that mediate the binding of the 
hybrids are shown as sticks, and the “flap” loop is shown in blue. 
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In Vitro Biological Profiling of Enantiopure Rhein–Huprine Hybrids (+)- and (–)-7e. 
After the in vitro biological profiling of the racemic rhein–huprine hybrids, (±)-7e emerged as 
the most interesting member of the series, mainly by virtue of its outstanding BACE-1 inhibitory 
potency, but also because it was one of the most potent compounds of the series for hAChE, 
hBChE, AChE-induced and self-induced Aβ aggregation. To further optimize the lead of the 
series, the two enantiomers of 7e were synthesized separately (see above) and subjected to in 
vitro biological profiling with the aim of unveiling potential enantioselective interactions with 
the different targets. 
In agreement with the stereoselective interaction of the parent huprine Y, the levorotatory 
rhein–huprine hybrid (–)-7e was far more potent hAChE inhibitor than its enantiomer (+)-7e, 
with an enantioselectivity (1200-fold) somewhat more pronounced than that found for the parent 
huprine Y (430-fold) (Table 1), in agreement with the docking calculations (Figure 1). To further 
confirm the inhibition mechanism, a kinetic study of the interaction of (–)-7e with hAChE was 
also carried out. The mode of inhibition of (–)-7e was determined with the aid of Lineweaver-
Burk double reciprocal plot. The interception of the lines in the Lineweaver-Burk plot above the 
x-axis (Figure 3) demonstrated that (–)-7e acts as a mixed-type inhibitor of hAChE. 
The inhibitor dissociation constants Ki and K’i, which denote the dissociation constant for the 
enzyme–inhibitor and enzyme–substrate–inhibitor complexes respectively (see Experimental 
Section), were estimated and resulted to be 2.65 and 3.41 nM, respectively. 
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Figure 3. Kinetic study on the mechanism of AChE inhibition by (–)-7e. Overlaid Lineweaver–
Burk reciprocal plots of AChE initial velocity at increasing substrate concentration (ATCh, 0.56–
0.11 mM) in the absence and in the presence (0.84–3.65 nM) of (–)-7e are shown. Lines were 
derived from a weighted least-squares analysis of the data points. 
Contrary to the inhibition of hAChE by the enantiomers of huprines, for hBChE inhibition the 
eutomer is the dextrorotatory (7R,11R)-enantiomer, (+)-4. Thus, not unexpectedly, for hBChE 
inhibition, the rhein–huprine hybrid (+)-7e was 2-fold more potent than (–)-7e, the 
enantioselectivity being quite similar to that found for huprine Y (1.3-fold) (Table 1). 
In contrast to hAChE and hBChE inhibition and in agreement with the idea that the 
enantioselective inhibition of the cholinesterase catalytic activity is related to the interaction with 
CAS, no enantioselectivity was found in the inhibition by (+)- and (–)-7e of the AChE-induced 
aggregation of Aβ40 (37–38% inhibition at 100 μM). Similarly, no differences were highlighted 
 
19
for the inhibition of the self-induced aggregation of Aβ42 (38–43% inhibition at 10 μM), and 
hBACE-1 activity (IC50 80 nM in both enantiomers) by (+)- and (–)-7e. 
In Vitro Blood–Brain Barrier Permeation Assay. CNS drugs must be able to efficiently 
cross the blood–brain barrier (BBB). However, cell permeability and brain penetration constitute 
a major hurdle in the development of some classes of anti-Alzheimer drugs, particularly in 
BACE-1 inhibitors and in Aβ and tau aggregation inhibitors.4,31,60,64 Moreover, compounds 
designed by combination of two pharmacophoric moieties, such as the novel rhein–huprine 
hybrids, usually have molecular weights over 500, which might challenge their ability to cross 
cell membranes.65,66 However, different families of anti-Alzheimer hybrid compounds with 
molecular weights over 500 have shown good oral availability and/or brain permeability in ex 
vivo and in vivo studies in mice.12,40,67,68 Even though the potential of a CNS drug to enter into 
the brain also depends on a low P-glycoprotein efflux liability,69,70 a good brain permeability is a 
necessary requirement. In this work, the brain permeability of the novel rhein–huprine hybrids 
has been predicted through the widely known parallel artificial membrane permeation assay 
(PAMPA-BBB).71 The in vitro permeability (Pe) of racemic rhein–huprine hybrids through a 
lipid extract of porcine brain was determined using phosphate-buffered saline (PBS)/EtOH 
70:30. Assay validation was carried out by comparing the experimental and literature 
permeability values of 14 commercial drugs (Table S1, Supporting Information), which gave a 
good linear correlation: Pe (exp) = 1.4525 Pe (lit) – 0.4926 (R2 = 0.9199). Using this equation 
and the limits established by Di et al. for BBB permeation,71 the following ranges of 
permeability were established: Pe (10–6 cm s–1) > 5.3 for compounds with high BBB permeation 
(CNS+); Pe (10–6 cm s–1) < 2.4 for compounds with low BBB permeation (CNS–); and 5.3 > Pe 
(10–6 cm s–1) > 2.4 for compounds with uncertain BBB permeation (CNS+/–). All the tested 
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rhein–huprine hybrids were predicted to be able to cross BBB, their measured Pe values being far 
above the threshold for high BBB permeation (Table 1), as it is also the case for the parent 
huprine Y, (±)-4, but not for rhein, 3, for which an uncertain BBB permeability was predicted. 
Indeed, rhein is therapeutically used against arthritis in the form of the more lipophilic and cell 
permeable doubly acetylated prodrug diacerein. 
Inhibition of Aβ42 and Tau Aggregation in Intact Escherichia coli Cells. The aggregation 
of two amyloidogenic proteins, namely Aβ and tau, plays a pivotal role in the pathological 
network of AD. Protein aggregation also occurs during the production of heterologous proteins 
in bacteria, leading to the formation of insoluble inclusion bodies (IBs). Because IBs contain 
highly ordered amyloid-like structures and their formation seems to share mechanistic features 
with amyloid self-assembly, they have been recently proposed as a model to study amyloid 
aggregation.72,73 We have recently developed a methodology that allows a fast, simple, and 
inexpensive evaluation of the anti-aggregating activity of putative inhibitors, which is based on 
the in vivo staining with thioflavin S of IBs in intact E. coli cells that overexpress a given 
amyloidogenic protein in the presence and absence of the inhibitors, and monitoring of the 
corresponding changes in the fluorescence of thioflavin S.74 The applicability of this method to 
the screening of both Aβ42 and tau aggregation inhibitors has been recently demonstrated.74 
Worthy of note, the Aβ42 anti-aggregating activities determined through this method for a 
number of known active and inactive inhibitors were very similar to those previously reported in 
in vitro assays using synthetic peptides, thereby validating this methodology.74 A potential 
limitation of this method lies in the fact that only compounds that are membrane permeable can 
be detected, whereas potential hits that are active as aggregation inhibitors but unable to cross 
biological membranes would remain undetected. In the light of the results obtained in the 
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PAMPA-BBB assays this should not be an issue for the novel rhein–huprine hybrids, which were 
tested for their ability to inhibit both Aβ42 and tau aggregation in intact E. coli cells (Table 2). 
 
Table 2. Inhibitory Activities of the Hydrochlorides of RheinHuprine Hybrids and 
Reference Compounds Toward Aβ42 and Tau Aggregation in Intact E. coli Cellsa 
compd Aβ42  aggregation 
(% inhibition)b 
tau  aggregation 
(% inhibition)b 
(±)-7a 68.0 ± 0.8 43.7 ± 1.1 
(±)-7b 68.4 ± 8.9 30.9 ± 3.1 
(±)-7c 63.2 ± 9.8 52.0 ± 1.1 
(±)-7d 50.2 ± 5.6 29.2 ± 1.3 
(±)-7e 47.9 ± 14.5 29.6 ± 8.5 
(+)-7e 58.6 ± 7.1 24.9 ± 0.4 
(–)-7e 47.2 ± 5.1 34.3 ± 0.1 
(±)-7f 43.3 ± 4.1 57.1 ± 1.9 
(±)-7g 40.7 ± 2.2 46.3 ± 0.7 
(±)-7h 57.9 ± 0.0 23.1 ± 5.1 
3 49.9 ± 6.4 40.8 ± 0.7 
(±)-4 nac nac 
a Values are expressed as mean ± standard error of the mean (SEM) of four independent 
experiments (n=4). b % inhibition with inhibitor at 10 μM. c Not active. 
 
All the rhein–huprine hybrids exhibited a moderately potent Aβ42 anti-aggregating activity in 
E. coli cells, with percentages of inhibition in the range 41–68% at 10 μM, and, hence, with IC50 
values below 10 μM in most cases (Table 2). Some clear SAR trends became apparent, namely a 
higher Aβ42 anti-aggregating activity for the hybrids with the shortest oligomethylene linkers 
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and for the dextrorotatory over the levorotatory enantiomer of 7e. The presence of an aromatic 
ring within the linker seemed not to be detrimental for Aβ42 anti-aggregating activity, hybrid 
(±)-7h displaying a notable 58% inhibition at 10 μM, albeit slightly lower than that of the 
oligomethylene-linked hybrid of similar tether length, (±)-7b. Interestingly, the Aβ42 anti-
aggregating activities measured for the rhein–huprine hybrids in intact E. coli cells were of 
similar magnitude than those determined in the in vitro assay, albeit somewhat higher in most 
cases. Regarding the parent compounds, huprine Y was found to be essentially inactive in E. coli 
as it was in the in vitro assay, whereas rhein, which could not be evaluated in vitro for solubility 
problems under the assay conditions, was found to exhibit an interesting 50% inhibition at 10 
μM in E. coli cells. 
In agreement with our design strategy, the parent hydroxyanthraquinone derivative rhein was 
found to be active as inhibitor of tau aggregation in intact E. coli cells (41% inhibition at 10 μM), 
and this was also the case for the novel rhein–huprine hybrids (23–57% inhibition at 10 μM), but 
not for the parent huprine Y, which was inactive, as expected (Table 2). For the inhibitory 
activity on tau aggregation, the presence of an aromatic ring within the linker seemed to be 
detrimental and the levorotatory enantiomer of 7e was more potent than (+)-7e. However, a clear 
SAR trend regarding the length of the linker could not be derived. 
The dual Aβ42 and tau anti-aggregating action of the novel rhein–huprine hybrids seems very 
promising for anti-Alzheimer drug candidates. These results are also important in the context of 
the treatment of amyloidoses in general, insofar as they support the increasingly accepted notion 
that all diseases that involve the pathological aggregation of a particular protein might share 
common mechanisms and common therapeutic interventions.75,76 Indeed, other examples of 
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compounds able to inhibit the aggregation of several amyloidogenic proteins have been 
reported.40,75,77 
Protection Against the Synaptic Failure Induced by Aβ Oligomers in Hippocampal Slices 
of C57bl6 Mice. In the light of the outstanding multi-target pharmacological profile found in 
vitro and in E. coli cells for the enantiopure rhein–huprine hybrids (+)- and (–)-7e, involving the 
modulation of crucial targets of the pathological network of AD, these compounds were selected 
as leads for further pharmacological characterization. 
Even though all aggregated forms of Aβ are likely pathological,78 it has been reported that Aβ 
oligomers (Aβ-o) cause an impairment of synaptic functions observed in AD patients and mouse 
models of AD.79 Because the target of Aβ-o is located at the postsynaptic region,80,81 processes 
associated to synaptic plasticity as long-term potentiation (LTP) are critically altered, leading to 
diminished synaptic strength and efficacy. These dysfunctions are correlated with reduction in 
the levels of synaptic proteins that participate in events associated with learning and memory 
such as glutamatergic receptors and scaffold proteins.82 To further assess the disease-modifying 
effects of the rhein–huprine hybrids (+)- and (–)-7e, their potential protective effect on synaptic 
integrity was assessed in hippocampal slices of 2-month-old C57bl6 male mice incubated with 
Aβ42 oligomers. 
Electrophysiological Assays. Firstly, electrophysiological registers of the hippocampal slices 
were used to evaluate synaptic transmission through the LTP. Hippocampal slices were 
incubated with Aβ42 oligomers (1 μM) 10 min prior and 10 min after LTP induction. No 
induction of LTP was observed in hippocampal slices incubated either with Aβ42 oligomers 
alone or with Aβ42 oligomers and (–)-7e (10 μM) (Figure 4A, white circles and light grey 
circles, respectively). On the contrary, treatment with (+)-7e (10 μM) led to a 200% LTP 
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induction (Figure 4A, dark grey circles), similarly to the effect found in the control slices treated 
only with artificial cerebrospinal fluid (ACSF). In Figure 4B, the quantification at min 60 of the 
field excitatory postsynaptic potentials (fEPSP) are shown. Treatment with (+)-7e led to a 200% 
magnitude response when compared to slices treated either with Aβ42 oligomers alone or with 
Aβ42 oligomers and (–)-7e. These results indicate that (+)-7e protects against the synaptic failure 
induced by acute treatments with Aβ42 oligomers, within the context of LTP induction. 
A       B 
 
 
 
 
 
Figure 4. Electrophysiological assays in hippocampal slices of 2-month-old C57bl6 mice 
incubated with Aβ oligomers (1 μM) and (+)- or (–)-7e (10 μM). (A) Electrophysiological 
registers. (B) Quantification of field excitatory postsynaptic potentials (fEPSP). 
 
Synaptic Protein Levels. Changes in the synaptic protein levels of hippocampal slices of 2-
month-old C57bl6 mice treated with Aβ42 oligomers and different concentrations of (+)- and (–
)-7e (1–100 μM) for 1 h were studied by densitometric analysis of western blots gels. Treatment 
of the hippocampal slices with Aβ42 oligomers (Figure 5, black bars) produced a decrease in the 
levels of the postsynaptic proteins GluA2 (a subunit of the AMPA receptor) and PSD95 
(postsynaptic density protein 95, a scaffold protein within the postsynaptic density), and of the 
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presynaptic proteins synapsin (SYN) and the vesicular glutamate transporter 1 (VGlut1) in 
comparison with control slices (Figure 5, white bars), whereas the levels of the presynaptic 
protein synaptophysin (SYP) remained unchanged. In hippocampal slices co-treated with (–)-7e 
(Figure 5A) a neuroprotective effect was observed. Evident increases in the levels of GluA2 and 
PSD95 were observed at 10 and 100 μM, and in the levels of VGlut1 for every used 
concentration of (–)-7e, whereas increases in the levels of SYN and SYP were found only at the 
highest assayed concentration or were not observed. Co-treatment with (+)-7e produced 
increases, albeit more modest, in the levels of GluA2, PSD95 and SYN with every used 
concentration, whereas it had no effect on the levels of VGlut1 and SYP. Thus, both (+)- and (–)-
7e exert a protective effect on synaptic proteins related with the stability of the synapses and the 
synaptic plasticity in the hippocampus. 
Prevention of the Aβ-o-induced loss of synaptic proteins by treatment of hippocampal slices of 
2-month-old C57bl6 mice with (+)-7e is in agreement with the results found in the 
electrophysiological assays and with the anti-amyloid activities found in the in vitro and in E. 
coli assays, namely its potent BACE-1 and Aβ aggregation inhibitory activities. Thus, the 
protective effects of (+)-7e and also (–)-7e on synaptic integrity might be ascribed to a reduction 
of the amount of Aβ aggregated species or to a reduction of Aβ production through the inhibition 
of APP processing, although participation of alternative or additional mechanisms can not be 
ruled out. For example, it has been reported that the increased levels of neurotransmitter 
acetylcholine due to AChE inhibition may promote changes in synaptic plasticity improving 
LTP.83,84 Indeed, (–)-7e, the eutomer for hAChE inhibition, seems to be more potent regarding 
the preservation of synaptic proteins, even though it does not improve LTP. Different 
mechanisms are likely involved in the neuroprotective effect shown by (+)- and (–)-7e. 
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Figure 5. Synaptic protein levels of hippocampal slices of 2-month-old C57bl6 mice incubated 
with Aβ oligomers and (–)-7e (A) or (+)-7e (B). 
 
27
In Vivo Aβ Lowering Effect. Among the different interesting biological activities found in 
vitro, in E. coli, and ex vivo for the enantiopure rhein–huprine hybrids (+)-7e and (–)-7e, likely 
the most notable effect is the potent inhibition of BACE-1 (IC50 80 nM). To gain further insight 
into the relevance of this activity, we have determined the in vivo effects of (+)-7e and (–)-7e on 
the level of total soluble Aβ oligomers, thought to be involved in synapse destruction and 
memory impairment in AD.85 To this end, we used a well-established animal model of AD, 
namely the double transgenic mice APP-PS1 (see Experimental Section). This aggressive model 
of AD has been characterized both in the generation of senile plaques in the brain and in their 
behavioral changes,86 describing the age at which these animals exhibit early senile plaques and 
cognitive impairment from 7 months of age, which occur mainly in the cortex and 
hippocampus.86 6- and 10-month-old APP-PS1 mice were treated with 2 mg/kg of (+)-7e or (–)-
7e intraperitoneally three times per week for 4 weeks to evaluate the effects of these compounds 
on the production and aggregation of Aβ species in two different stages of the AD model; initial 
and severe, respectively. The soluble protein fraction from hippocampus homogenates of control 
and treated APP-PS1 mice was separated in tris-tricine gels, each lane being a different mouse, 
and specific mouse anti-β peptide 6E10 antibody was used, followed by immunoblot analysis. 
Young (7-month-old after the treatment; n=3 control; n=3 (+)-7e treated; and n=2 (–)-7e 
treated APP-PS1 mice) and aged (11-month-old after the treatment; n=3 control; n=3 (+)-7e 
treated; and n=3 (–)-7e treated APP-PS1 mice) APP-PS1 mice exhibit several forms of Aβ 
peptides, including hexamers (ca. 24 kDa) and higher levels of Aβ dodecamers (ca. 56 kDa). 
Interestingly, young and aged APP-PS1 mice treated with (+)-7e showed a significant decrease 
in the levels of dodecamers, whereas only in young mice a reduction in the levels of hexamers 
was observed (Figures 6 and 7). In addition, young APP-PS1 mice treated with (–)-7e showed a 
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tendency toward decreased levels of both oligomeric species, whereas aged APP-PS1 mice 
treated with (–)-7e showed a diminution in the levels of dodecamers, without altering the levels 
of hexamers (Figures 6 and 7). The results observed in 11-month-old mice might be due to the 
high load of Aβ present in aging APP-PS1 mice. However the reduction in the levels of 
dodecamers, considered to be synaptotoxic, is very important, because it might be indicative of a 
reversion in the neurodegenerative process observed in the animal. More studies are necessary to 
corroborate this possibility. Together, these results suggest that rhein–huprine hybrids (+)-7e and 
(–)-7e either could favor the formation of senile plaques and the decrease of the soluble Aβ 
forms or prevent the APP processing and the subsequent aggregation, through inhibition of 
BACE-1. To corroborate the last hypothesis, the levels of APP protein were analyzed in the same 
gel described before where each lane represents an independent animal. The results showed that 
in young and aged APP-PS1 mice treated with (+)-7e and (–)-7e the levels of mature APP (ca. 
100 KDa) are increased (Figures 6 and 7), indicating that these rhein–huprine hybrids are able to 
prevent APP processing, Aβ production and aggregation. 
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 Figure 6. Soluble Aβ and APP protein levels of hippocampal samples from 7-month-old APP-
PS1 mice treated with (–)-7e or (+)-7e for 4 weeks. Lanes 1-3 show hippocampus lysates from 
control mice (n=3), lanes 4-6 show hippocampus lysates from (+)-7e treated mice (n=3) and 
lanes 7-8 show hippocampus lysates from (–)-7e treated mice (n=2), each lane being an 
independent animal. 
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 Figure 7. Soluble Aβ and APP protein levels of hippocampal samples from 11-month-old APP-
PS1 mice treated with (–)-7e or (+)-7e for 4 weeks. Lanes 1-3 show hippocampus lysates from 
control mice (n=3), lanes 4-6 show hippocampus lysates from (+)-7e treated mice (n=3) and 
lanes 7-9 show hippocampus lysates from (–)-7e treated mice (n=3), each lane being an 
independent animal. 
 
CONCLUSIONS 
We have synthesized a series of racemic and enantiopure hybrid compounds that combine a 
unit of the hydroxyanthraquinone drug rhein and a unit of the potent AChE’s CAS inhibitor 
huprine Y, connected through penta- to undeca-methylene or 1,4-phenylene-bis(methylene) 
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linkers. These hybrids were purportedly designed to exhibit a multi-target profile of interest for 
the efficient management of AD, which included the inhibitory actions expected for dual binding 
site inhibitors of AChE against the catalytic and the Aβ-proaggregating activities of this enzyme 
and the tau anti-aggregating effect known for some hydroxyanthraquinone compounds similar to 
rhein. In agreement with the design rationale, the novel rhein–huprine hybrids are endowed with 
very potent hAChE inhibitory activity and moderately potent inhibitory activities against 
hAChE-induced and self-induced aggregation of Aβ and against hBChE. Far beyond our 
expectations, some rhein–huprine hybrids additionally display a very potent BACE-1 inhibitory 
activity. Of note, these hybrids have been predicted to be able to cross BBB using an artificial 
membrane model, likely having the ability to exert the same actions in vivo. Both cell 
permeability and the Aβ anti-aggregating activity found in vitro for the rhein–huprine hybrids, as 
well as their expected tau anti-aggregating activity, have been confirmed by some assays based 
on the direct thioflavin S staining of IBs in intact E. coli cells that were genetically altered to 
overexpress Aβ42 and tau protein. On the basis of the biological profiling in vitro and in E. coli, 
(+)- and (–)-7e have been selected as lead rhein–huprine hybrids and their protective effects 
against the synaptic failure induced by Aβ oligomers in hippocampal slices of 2-month-old 
C57bl6 mice have been assessed. These studies have shown that both hybrids prevent the loss of 
synaptic proteins. Additionally, the beneficial effects of (+)-7e on synaptic integrity were 
apparent in the context of LTP induction. Finally, in vivo experiments with transgenic APP-PS1 
mice have shown that (+)- and (–)-7e are able to lower the levels of hippocampal total soluble 
Aβ and increase the levels of APP both in initial and advanced stages of this AD model, thus 
suggesting a reduction of APP processing, as expected from their potent BACE-1 inhibitory 
activity. Overall, the novel rhein–huprine hybrids (+)- and (–)-7e emerge as very promising 
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multi-target anti-Alzheimer drug candidates with potential to positively modify the underlying 
mechanisms of this disease. 
 
 EXPERIMENTAL SECTION 
Chemistry. Melting points were determined in open capillary tubes with a MFB 595010M 
Gallenkamp melting point apparatus. 400 MHz 1H/100.6 MHz 13C NMR spectra, and 500 MHz 
1H/125.7 MHz 13C NMR spectra were recorded on Varian Mercury 400, and Varian Inova 500 
spectrometers, respectively. The chemical shifts are reported in ppm (δ scale) relative to internal 
tetramethylsilane, and coupling constants are reported in Hertz (Hz). Assignments given for the 
NMR spectra of the new compounds have been carried out on the basis of DEPT, COSY 1H/1H 
(standard procedures), and COSY 1H/13C (gHSQC or gHMBC sequences) experiments. The syn 
(anti) notation of the protons at position 13 of the huprine moiety of the hybrids means that the 
corresponding proton at position 13 is on the same (different) side of the quinoline moiety with 
respect to the cyclohexene ring. IR spectra were run on a Perkin-Elmer Spectrum RX I 
spectrophotometer. Absorption values are expressed as wave-numbers (cm1); only significant 
absorption bands are given. Optical rotations were measured on a Perkin-Elmer model 241 
polarimeter. The specific rotation has not been corrected for the presence of solvent of 
crystallization. Column chromatography was performed on silica gel 60 AC.C (4060 mesh, 
SDS, ref 2000027). Thin-layer chromatography was performed with aluminum-backed sheets 
with silica gel 60 F254 (Merck, ref 1.05554), and spots were visualized with UV light and 1% 
aqueous KMnO4. NMR spectra of all of the new compounds were performed at the Centres 
Científics i Tecnològics of the University of Barcelona (CCiTUB), while elemental analyses and 
high resolution mass spectra were carried out at the Mycroanalysis Service of the IIQAB (CSIC, 
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Barcelona, Spain) with a Carlo Erba 1106 analyzer, and at the CCiTUB with a LC/MSD TOF 
Agilent Technologies spectrometer, respectively. The synthetic procedures for the preparation of 
the intermediate nitriles 5a–h and amines 5a–h are exemplified through the synthesis of 5a and 
6a. The synthesis of the rest of nitriles and amines is included in the Supporting Information.  
The analytical samples of all of the rheinhuprine hybrids which were subjected to 
pharmacological evaluation possess a purity 95% as evidenced by their elemental analyses. 
(±)-5-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]pentanenitrile [(±)-5a]. A suspension of (±)-huprine Y, (±)-4 (300 mg, 1.06 mmol) 
and finely powdered KOH (85% purity, 139 mg, 2.11 mmol), and 4 Å molecular sieves in anhyd 
DMSO (6 mL) was stirred, heating every 10 min approximately with a heat gun for 1 h and at rt 
one additional hour, and then treated with 5-bromovaleronitrile (0.15 mL, 208 mg, 1.28 mmol). 
The reaction mixture was stirred at rt overnight, diluted with 5N NaOH (25 mL) and extracted 
with EtOAc (340 mL). The combined organic extracts were washed with H2O (350 mL), dried 
over anhyd Na2SO4, and evaporated under reduced pressure to give a yellow oil (469 mg), which 
was purified by column chromatography (4060 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH 
mixtures, gradient elution). On elution with CH2Cl2/50% aq. NH4OH 100:0.2, the N,N-
dialkylated derivative (±)-8a (78 mg, 16% yield) was isolated as a yellow oil. On elution with 
CH2Cl2/MeOH/50% aq. NH4OH 99:1:0.2, nitrile (±)-5a (273 mg, 70% yield) was isolated as a 
beige solid; Rf[(±)-5a] 0.50; Rf[(±)-8a] 0.77 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of (±)-5a (52 mg, 0.14 mmol) in CH2Cl2 (4.5 mL) was filtered through a 0.2 µm 
PTFE filter, treated with methanolic HCl (1.40N, 0.30 mL) and evaporated under reduced 
pressure. The resulting solid was washed with pentane (32 mL) to give, after drying at 65 ºC/2 
Torr for 48 h, (±)-5a·HCl (58 mg) as a yellow solid: mp 181183 °C (CH2Cl2/MeOH 94:6); IR 
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(KBr) ν 35002500 (max at 3364, 3254, 3049, 3014, 2926, 2885, 2651, N-H, N+-H and C-H st), 
2243 (CN st), 1635, 1629, 1602, 1582, 1570, 1562 (ar-C-C and ar-C-N st) cm1; 1H NMR (400 
MHz, CD3OD) δ 1.59 (s, 3H, 9’-CH3), 1.79 (tt, J≈J’≈7.2 Hz, 2H, 3-H2), 1.93 (d, J=17.6 Hz, 1H, 
10’-Hendo), superimposed in part 1.92–1.98 (m, 1H, 13’-Hsyn), 2.01 (tt, J≈J’≈7.2 Hz, 2H, 4-H2), 
2.09 (dm, J=12.8 Hz, 1H, 13’-Hanti), 2.56 (t, J=7.2 Hz, 2H, 2-H2), superimposed in part 
2.532.60 (m, 1H, 10’-Hexo), 2.77 (m, 1H, 7’-H), 2.88 (ddd, J=18.0 Hz, J’=J”=1.6 Hz, 1H, 6’-
Hendo), 3.22 (dd, J=18.0 Hz, J’=5.2 Hz, 1H, 6’-Hexo), 3.47 (m, 1H, 11’-H), 4.03 (t, J= 7.6 Hz, 2H, 
5-H2), 4.85 (s, NH and +NH), 5.59 (br d, J=4.4 Hz, 1H, 8’-H), 7.57 (dd, J=9.2 Hz, J’=2.0 Hz, 
1H, 2’-H), 7.78 (d, J≈2.0 Hz, 1H, 4’-H), 8.40 (d, J≈9.2 Hz, 1H, 1’-H); 13C NMR (100.6 MHz, 
CD3OD) δ 17.1 (CH2, C2), 23.4 (CH3, 9’-CH3), 23.9 (CH2, C3), 27.3 (CH, C11’), 27.9 (CH, 
C7’), 29.3 (CH2, C13’), 30.3 (CH2, C4), 36.1 (CH2), 36.2 (CH2) (C6’, C10’), 48.8 (CH2, C5), 
115.8 (C, C12a’), 117.9 (C, C11a’), 119.2 (CH, C4’), 120.9 (C, CN), 125.1 (CH, C8’), 126.8 
(CH, C2’), 129.4 (CH, C1’), 134.6 (C, C9’), 140.3 (C, C3’), 141.0 (C, C4a’), 151.5 (C, C5a’), 
157.0 (C, C12’). HRMS (ESI) calcd for (C22H2435ClN3 + H+): 366.1732, found 366.1729. 
A solution of (±)-8a (78 mg, 0.17 mmol) in CH2Cl2 (4.5 mL) was filtered through a 0.2 µm 
PTFE filter, treated with methanolic HCl (0.65N, 0.64 mL) and evaporated under reduced 
pressure. The resulting solid was washed with pentane (32 mL) to give, after drying at 65 ºC/2 
Torr for 48 h, (±)-8a·HCl (80 mg) as a yellow solid: mp 196198 ºC (CH2Cl2/MeOH 88:12); IR 
(KBr) ν 3500–2450 (max at 3430, 3044, 2919, 2875, 2464, N+-H and C-H st), 2243 (CN st), 
1632, 1604, 1574 (ar-C-C and ar-C-N st) cm1; 1H NMR (400 MHz, CD3OD) δ 1.59 (s, 3H, 9’-
CH3), 1.65 (tt, J≈J’≈7.2 Hz, 4H, 3-H2), 1.721.98 (complex signal, 4H, 4-H2), 2.00 (br d,  J=17.6 
Hz, 1H, 10’-Hendo), superimposed in part 2.06 (dm, J≈12.8 Hz, 1H, 13’-Hsyn), 2.12 (dm, J=12.8 
Hz, 1H, 13’-Hanti), 2.48 (t, J=7.2 Hz, 4H, 2-H2), 2.69 (dd, J=17.6 Hz, J’=5.6 Hz, 1H, 10’-Hexo), 
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2.82 (m, 1H, 7’-H), 3.17 (ddd, J=18.0 Hz, J’≈J”≈1.8 Hz, 1H, 6’-Hendo), 3.39 (dd, J=18.0 Hz, 
J’=5.6 Hz, 1H, 6’-Hexo), superimposed in part 3.73 (m, 1H, 11’-H), 3.73 (ddd, J=13.6 Hz, J’=9.6 
Hz, J”=5.6 Hz, 2H) and 3.80 (ddd, J=13.6 Hz, J’=9.2 Hz, J”=6.0 Hz, 2H) (5-H2), 4.84 (s, +NH), 
5.68 (br d, J=4.4 Hz, 1H, 8’-H), 7.72 (dd, J=9.2 Hz, J’=2.4 Hz, 1H, 2’-H), 7.99 (d, J=2.4 Hz, 1H, 
4’-H), 8.26 (d, J=9.2 Hz, 1H, 1’-H); 13C NMR (100.6 MHz, CD3OD) δ 17.1 (CH2, C2), 23.3 
(CH3, 9’-CH3), 23.9 (CH2, C3), 27.6 (CH, C7’), 28.6 (CH2, C13’), 28.9 (CH2, C4), 29.7 (CH, 
C11’), 37.7 (CH2, C6’), 38.7 (CH2, C10’), 55.1 (CH2, C5), 120.0 (CH, C4’), 120.9 (C, CN), 
125.5 (C, C12a’), 125.7 (CH, C8’), 192.2 (CH, C2’), 130.1 (CH, C1’), 132.5 (C, C11a’), 134.3 
(C, C9’), 140.36 (C), 140.43 (C) (C3’, C4a’), 157.6 (C, C5a’), 163.9 (C, C12’); HRMS (ESI) 
calcd for (C27H3135ClN4 + H+) 447.2310, found 447.2309. 
(±)-N-(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)pentane-1,5-diamine [(±)-6a]. To a suspension of LiAlH4 (0.17 g, 4.47 mmol) in anhyd Et2O 
(63 mL), nitrile (±)-5a (0.76 g, 2.08 mmol) was added, and the reaction mixture was stirred at rt 
overnight. The resulting mixture was treated with wet Et2O (200 mL) and evaporated under 
reduced pressure. The solid was suspended in CH2Cl2, filtered through Celite® and evaporated 
under reduced pressure, to give amine (±)-6a (750 mg, 98% yield) as a yellow oil; Rf 0.03 
(CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of (±)-6a (50 mg, 0.14 mmol) in CH2Cl2 (3.5 mL) was filtered through a 0.2 µm 
PTFE filter, treated with methanolic HCl (1.4N, 0.87 mL), and evaporated under reduced 
pressure. The resulting solid was washed with pentane (32 mL) to give, after drying at 65 ºC/2 
Torr for 48 h, (±)-6a·2HCl (54 mg) as a yellow solid: mp 193194 ºC (CH2Cl2/MeOH 80:20); IR 
(KBr) ν 3500–2500 (max at 3396, 3253, 2925, 2856, N-H, N+-H and C-H st), 1628, 1583, 1570, 
1558 (ar-C-C and ar-C-N st) cm1; 1H NMR (400 MHz, CD3OD) δ 1.55 (tt, J≈J’≈7.6 Hz, 2H, 3-
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H2), 1.59 (s, 3H, 9’-CH3), 1.76 (m, 2H, 4-H2), 1.902.02 (complex signal, 4H, 10’-Hendo, 13’-
Hsyn, 2-H2), 2.09 (dm,  J=12.8 Hz, 1H, 13’-Hanti), 2.57 (ddm, J=17.6 Hz, J’=6.0 Hz, 1H, 10’-
Hexo), 2.78 (m, 1H, 7’-H), 2.87 (br d, J=18.0 Hz, 1H, 6’-Hendo), 2.97 (t, J=7.6 Hz, 2H, 5-H2), 3.21 
(dd, J=18.0 Hz, J’=5.6 Hz, 1H, 6’-Hexo), 3.49 (m, 1H, 11’-H), 4.01 (t, J≈7.6 Hz, 2H, 1-H2), 4.85 
(s, NH and +NH),  5.59 (br d, J=4.4 Hz, 1H, 8’-H), 7.57 (dd,  J=9.2 Hz, J’=2.0 Hz, 1H, 2’-H), 
7.78 (d, J=2.0 Hz, 1H, 4’-H), 8.41 (d, J=9.2 Hz, 1H, 1’-H); 13C NMR (100.6 MHz, CD3OD) δ 
23.5 (CH3, 9’-CH3), 24.7 (CH2, C3), 27.3 (CH, C11’), 27.9 (CH, C7’), 28.2 (CH2, C4), 29.3 
(CH2, C13’), 30.8 (CH2, C2), 36.0 (CH2), 36.2 (CH2) (C6’, C10’), 40.5 (CH2, C5), 49.4 (CH2, 
C1), 115.7 (C, C12a’), 117.8 (C, C11a’), 119.2 (CH, C4’), 125.1 (CH, C8’), 126.8 (CH, C2’), 
129.4 (CH, C1’), 134.6 (C, C9’), 140.3 (C, C3’), 141.0 (C, C4a’), 151.4 (C, C5a’), 156.9 (C, 
C12’); HRMS (ESI) calcd for (C22H2835ClN3 + H+) 370.2045, found 370.2041. 
(±)-N-{5-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]pentyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide [(±)-
7a]. A suspension of rhein, 3 (477 mg, 1.68 mmol), in anhyd CH2Cl2 (6 mL) was cooled to 0 ºC 
with an ice bath, and treated dropwise with freshly distilled Et3N (0.47 mL, 341 mg, 3.38 mmol) 
and ClCO2Et (0.16 mL, 182 mg, 1.68 mmol). The resulting solution was stirred at 0 ºC for 30 
min and treated with a solution of amine (±)-6a (621 mg, 1.68 mmol) in anhyd CH2Cl2 (6 mL). 
The reaction mixture was stirred at rt for 3 days, diluted with 10% aq. Na2CO3 (50 mL), the 
phases were separated and the aqueous phase was extracted with CH2Cl2 (335 mL). The 
combined organic extracts were dried over anhyd Na2SO4 and evaporated under reduced 
pressure, to give a red solid (770 mg), which was purified by column chromatography (4060 
µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient elution). On elution with 
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CH2Cl2/MeOH/50% aq. NH4OH 99:1:0.2, hybrid (±)-7a (140 mg, 13% yield) was isolated as a 
red solid; Rf 0.45 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
A solution of hybrid (±)-7a (79 mg, 0.12 mmol) in CH2Cl2 (4 mL) was filtered through a 0.2 
µm PTFE filter, treated with methanolic HCl (1.4N, 0.26 mL) and evaporated under reduced 
pressure. The resulting solid was washed with pentane (32 mL) to give, after drying at 65 ºC/2 
Torr for 48 h, (±)-7a·HCl (80 mg) as a yellow solid: mp 213215 °C (CH2Cl2/MeOH 94:6); IR 
(KBr) ν 35002500 (max at 3224, 3047, 3005, 2923, 2852, O-H, N-H, N+-H and C-H st), 1669, 
1628, 1582, 1565 (C=O, ar-C-C and ar-C-N st) cm1; 1H NMR (500 MHz, CD3OD) δ 1.541.64 
(complex signal, 2H, 3’-H2), superimposed in part 1.59 (s, 3H, 9”-CH3), 1.77 (tt, J≈J’≈7.0 Hz, 
2H, 2’-H2), superimposed in part 1.902.00 (complex signal, 3H, 4’-H2, 13”-Hsyn), 1.94 (d,  
J≈17.0 Hz, 1H, 10”-Hendo), 2.08 (br d, J=12.5 Hz, 1H, 13”-Hanti), 2.56 (br dd, J=17.0 Hz, J’=4.0 
Hz, 1H, 10”-Hexo), 2.77 (m, 1H, 7”-H), 2.84 (d, J=17.5 Hz, 1H, 6”-Hendo), 3.18 (dd, J=17.5 Hz, 
J’=5.5 Hz, 1H, 6”-Hexo), 3.423.52 (complex signal, 3H, 1’-H2, 11”-H), 4.00 (dt, J=J’=7.5 Hz, 
2H, 5’-H2), 4.87 (s, NH, +NH and OH), 5.58 (br d, J=4.5 Hz, 1H, 8”-H), 7.35 (dd, J=7.5 Hz, 
J’=2.0 Hz, 1H, 6-H), 7.47 (br d, J=8.5 Hz, 1H, 2”-H), 7.62 (br s, 2H, 3-H, 4”-H), 7.76 (d, J=7.5 
Hz, 1H, 8-H), 7.78 (dd, J=J’=7.5 Hz, 1H, 7-H), 8.04 (s, 1H, 1-H), 8.34 (d, J=8.5 Hz, 1H, 1”-H); 
13C NMR (125.7 MHz, CD3OD) δ 23.5 (CH3, 9”-CH3), 25.1 (CH2, C3’), 27.3 (CH, C11”), 27.9 
(CH, C7”), 29.3 (CH2, C13”), 29.9 (CH2, C2’), 31.0 (CH2, C4’), 36.1 (CH2, C6”), 36.2 (CH2, 
C10”), 40.7 (CH2, C1’), 49.5 (CH2, C5’), 115.7 (C, C12a”), 117.0 (C, C10a), 117.6 (C, C11a”), 
118.6 (C, C4a), 118.8 (CH, C1), 119.1 (CH, C4”), 120.9 (CH, C8), 123.7 (CH, C3), 125.1 (CH, 
C8”), 125.8 (CH, C6), 126.7 (CH, C2”), 129.3 (CH, C1”), 134.6 (C, C9”), 134.8 (C, C8a), 135.2 
(C, C9a), 138.8 (CH, C7), 140.2 (C, C3”), 140.9 (C, C4a”), 143.4 (C, C2), 151.4 (C, C5a”), 
156.7 (C, C12”), 163.4 (C, C4), 163.7 (C, C5), 167.3 (C, CONH), 182.2 (C, C9), 193.7 (C, C10); 
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HRMS (ESI) calcd for (C37H3435ClN3O5 + H+) 636.2260, found 636.2255. Anal. 
(C37H34ClN3O5·HCl·1.5H2O) C, H, N, Cl. 
(±)-N-{6-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]hexyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide 
[(±)-7b]. It was prepared as described for (±)-7a. From rhein, 3 (1.19 g, 4.18 mmol), and 
amine (±)-6b (1.60 g, 4.18 mmol), a red solid (2.00 g) was obtained and purified by column 
chromatography (4060 µm silica gel, hexane/EtOAc/MeOH/Et3N mixtures, gradient elution). 
On elution with hexane/EtOAc/MeOH/Et3N 10:90:0:0.2 to 0:80:20:0.2, hybrid (±)-7b (647 mg, 
24% yield) was isolated as a red solid; Rf 0.54 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
(±)-7b·HCl: mp 203205 °C (CH2Cl2/MeOH 89:11); IR (KBr) ν 35002500 (max at 3228, 
3042, 2927, 2859, 2722, O-H, N-H, N+-H and C-H st), 1627, 1586, 1570 (C=O, ar-C-C and ar-C-
N st) cm1; 1H NMR (500 MHz, CD3OD) δ 1.491.56 (complex signal, 4H, 3’-H2, 4’-H2), 1.59 
(s, 3H, 9”-CH3), 1.70 (tt, J≈J’≈6.7 Hz, 2H, 2’-H2), superimposed in part 1.871.94 (complex 
signal, 3H, 5’-H2, 13”-Hsyn), superimposed in part 1.94 (br d, J=17.5 Hz, 1H, 10”-Hendo), 2.07 
(dm, J=12.0 Hz, 1H, 13”-Hanti), 2.54 (br dd, J≈17.5 Hz, J’≈3.5 Hz, 1H, 10”-Hexo), 2.77 (m, 1H, 
7”-H), 2.82 (br d, J=18.0 Hz, 1H, 6”-Hendo), 3.17 (dd, J=18.0 Hz, J’=5.0 Hz, 1H, 6”-Hexo), 
3.393.49 (complex signal, 3H, 1’-H2, 11”-H), 3.96  (dt, J=J’=6.7 Hz, 2H, 6’-H2), 4.84 (s, NH, 
+NH and OH), 5.58 (br d, J=5.0 Hz, 1H, 8”-H), 7.35 (dd, J=7.5 Hz, J’=1.5 Hz, 1H, 6-H), 7.46 (d, 
J≈9.0 Hz, 1H, 2”-H), 7.60 (s, 1H, 4”-H), 7.64 (s, 1H, 3-H), superimposed in part 7.75 (d, J=8.0 
Hz, 1H, 8-H), superimposed in part 7.77 (dd, J≈J’≈8.0 Hz, 1H, 7-H), 8.07 (s, 1H, 1-H), 8.32 (d, 
J≈9.0 Hz, 1H, 1”-H); 13C NMR (125.7 MHz, CD3OD) δ 23.4 (CH3, 9”-CH3), 27.2 (CH, C11”), 
27.3 (2CH2, C3’, C4’), 27.9 (CH, C7”), 29.3 (CH2, C13”), 30.0 (CH2, C2’), 31.1 (CH2, C5’), 
36.1 (2CH2, C6”, C10”), 40.7 (CH2, C1’), 49.5 (CH2, C6’), 115.7 (C, C12a”), 117.0 (C, C10a), 
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117.7 (C, C11a”), 118.6 (C, C4a), 118.8 (CH, C1), 119.1 (CH, C4”), 120.9 (CH, C8), 123.7 (CH, 
C3), 125.1 (CH, C8”), 125.8 (CH, C6), 126.6 (CH, C2”), 129.4 (CH, C1”), 134.6 (C, C9”), 134.8 
(C, C8a), 135.3 (C, C9a), 138.8 (CH, C7), 140.2 (C, C3”), 141.0 (C, C4a”), 143.6 (C, C2), 151.3 
(C, C5a”), 156.8 (C, C12”), 163.4 (C, C4), 163.8 (C, C5), 167.3 (C, CONH), 182.2 (C, C9), 
193.8 (C, C10); HRMS (ESI) calcd for (C38H3635ClN3O5 + H+) 650.2416, found 650.2414. Anal. 
(C38H36ClN3O5·HCl·1.25H2O) C, H, N, Cl. 
(±)-N-{7-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]heptyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide [(±)-
7c]. It was prepared as described for (±)-7a. From rhein, 3 (1.43 g, 5.04 mmol), and amine (±)-6c 
(2.00 g, 5.04 mmol), a red solid (2.20 g) was obtained and purified by column chromatography 
(4060 µm silica gel, hexane/EtOAc/MeOH/Et3N mixtures, gradient elution). On elution with 
hexane/EtOAc/MeOH/Et3N 40:60:0:0.2 to 0:80:20:0.2, hybrid (±)-7c (864 mg, 26% yield) was 
isolated as a red solid; Rf 0.48 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
(±)-7c·HCl: mp 202203 °C (EtOAc/CH2Cl2/MeOH 75:19:6); IR (KBr) ν 35002500 (max at 
3048, 2926, 2855, 2742, O-H, N-H, N+-H and C-H st), 1654, 1628, 1593, 1583, 1569, 1546 
(C=O, ar-C-C and ar-C-N st) cm1; 1H NMR (500 MHz, CD3OD) δ 1.49 (complex signal, 6H, 
3’-H2, 4’-H2, 5’-H2), 1.58 (s, 3H, 9”-CH3), 1.69 (tt, J≈J’≈6.5 Hz, 2H, 2’-H2), superimposed in 
part 1.871.94 (complex signal, 3H, 6’-H2, 13”-Hsyn), superimposed in part 1.94 (br d, J≈18.0 
Hz, 1H, 10”-Hendo), 2.07 (dm, J=12.0 Hz, 1H, 13-Hanti), 2.53 (br dd, J=18.0 Hz, J’=5.0 Hz, 1H, 
10-Hexo), 2.75 (m, 1H, 7”-H), 2.79 (br d, J≈18.0 Hz, 1H, 6”-Hendo), 3.14 (dd, J≈18.0 Hz, J’=5.5 
Hz, 1H, 6”-Hexo), 3.373.48 (complex signal, 3H, 1’-H2, 11”-H), 3.92  (dt, J=7.5 Hz, J’=4.0 Hz, 
2H, 7’-H2), 4.84 (s, NH, +NH and OH), 5.58 (br d, J=5.0 Hz, 1H, 8”-H), 7.36 (dd, J=8.5 Hz, 
J’=1.0 Hz, 1H, 6-H), 7.44 (dd, J≈9.0 Hz, J’=2.0 Hz, 1H, 2”-H), 7.59 (d, J=2.0 Hz, 1H, 4”-H), 
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7.66 (d, J≈2.0 Hz, 1H, 3-H), 7.73 (dd, J=7.5 Hz, J’≈1.0 Hz, 1H, 8-H), 7.78 (dd, J≈J’≈7.5 Hz, 
1H, 7-H), 8.09 (d, J=2.0 Hz, 1H, 1-H), 8.26 (d, J=9.0 Hz, 1H, 1”-H); 13C NMR (125.7 MHz, 
CD3OD) δ 23.4 (CH3, 9”-CH3), 27.3 (CH, C11”), 27.6 (CH2), 27.7 (CH2) (C4’, C5’), 27.9 (CH, 
C7”), 29.3 (CH2, C13”), 29.7 (CH2), 29.9 (CH2) (C2’, C3’), 31.1 (CH2, C6’), 36.0 (CH2), 36.1 
(CH2) (C6”, C10”), 41.0 (CH2, C1’), 49.7 (CH2, C7’), 115.6 (C, C12a”), 117.1 (C, C10a), 117.6 
(C, C11a”), 118.6 (C, C4a), 118.7 (CH, C1), 119.2 (CH, C4”), 120.9 (CH, C8), 123.7 (CH, C3), 
125.1 (CH, C8”), 125.8 (CH, C6), 126.6 (CH, C2”), 129.3 (CH, C1”), 134.6 (C, C9”), 134.8 (C, 
C8a), 135.3 (C, C9a), 138.8 (CH, C7), 140.2 (C, C3”), 141.0 (C, C4a”), 143.7 (C, C2), 151.3 (C, 
C5a”), 156.6 (C, C12”), 163.5 (C, C4), 163.8 (C, C5), 167.4 (C, CONH), 182.2 (C, C9), 193.6 
(C, C10); HRMS (ESI) calcd for (C39H3835ClN3O5 + H+) 664.2573 found 664.2569. Anal. 
(C39H38ClN3O5·HCl·0.5H2O) C, H, N, Cl. 
(±)-N-{8-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]octyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide [(±)-7d]. 
It was prepared as described for (±)-7a. From rhein, 3 (213 mg, 0.75 mmol), and amine (±)-6d 
(307 mg, 0.75 mmol), a red solid (740 mg) was obtained and purified by column 
chromatography (4060 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient 
elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH 98:2:0.2 to 80:20:0.2, hybrid (±)-7d 
(80 mg, 16% yield) was isolated as a red solid; Rf 0.30 (CH2Cl2/MeOH/50% aq. NH4OH 
9:1:0.05). 
(±)-7d·HCl: mp 180182 °C (EtOAc/CH2Cl2/MeOH 66:17:17); IR (KBr) ν 35002500 (max 
at 3222, 3047, 3007, 2924, 2852, 2640, O-H, N-H, N+-H and C-H st), 1766, 1674, 1628, 1607, 
1582, 1566, 1522 (C=O, ar-C-C and ar-C-N st) cm1; 1H NMR (500 MHz, CD3OD) δ 1.44 
(complex signal, 8H, 3’-H2, 4’-H2, 5’-H2, 6’H2), 1.59 (s, 3H, 9”-CH3), 1.67 (tt, J≈J’≈7.0 Hz, 2H, 
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2’-H2), superimposed in part 1.86 (tt, J≈J’≈7.0 Hz, 2H, 7’-H2), superimposed 1.85−1.94 (m, 1H, 
13”-Hsyn), superimposed in part 1.93 (br d,  J≈18.0 Hz, 1H, 10”-Hendo), 2.06 (dm, J=12.0 Hz, 1H, 
13”-Hanti), 2.53 (br dd, J≈18.0 Hz, J’=4.5 Hz, 1H, 10”-Hexo), 2.75 (m, 1H, 7”-H), 2.82 (br d, 
J=18.0 Hz, 1H, 6”-Hendo), 3.13 (dd, J=18.0 Hz, J’=5.0 Hz, 1H, 6”-Hexo), 3.393.47 (complex 
signal, 3H, 1’-H2, 11”-H), 3.87  (dt, J≈J’≈6.0 Hz, 2H, 8’-H2), 4.86 (s, NH, +NH and OH), 5.58 
(br d, J=5.0 Hz, 1H, 8”-H), 7.26 (d, J=8.5 Hz, 1H, 6-H), 7.35 (d, J≈9.0 Hz, 1H, 2”-H), 7.54 (s, 
1H, 4”-H), 7.58 (s, 1H, 3-H), superimposed in part 7.57−7.61 (m, 1H, 8-H), 7.69 (dd, J≈J’≈8.0 
Hz, 1H, 7-H), 7.97 (s, 1H, 1-H), 8.19 (d, J=9.0 Hz, 1H, 1”-H); 13C NMR (125.7 MHz, CD3OD) δ 
23.5 (CH3, 9”-CH3), 27.2 (CH, C11”), 27.5 (CH2), 27.6 (CH2), (C5’, C6’), 27.8 (CH, C7”), 29.3 
(CH2, C13”), 29.86 (CH2), 29.92 (CH2), 30.0 (CH2) (C2’, C3’, C4’), 31.1 (CH2, C7’), 36.0 
(2CH2, C6”, C10”), 41.0 (CH2, C1’), 49.7 (CH2, C8’), 115.4 (C, C12a”), 116.7 (C, C10a), 117.5 
(C, C11a”), 118.3 (C, C4a), 118.8 (CH, C1), 119.0 (CH, C4”), 120.8 (CH, C8), 123.7 (CH, C3), 
125.1 (CH, C8”), 125.8 (CH, C6), 126.6 (CH, C2”), 129.2 (CH, C1”), 134.4 (C, C9”), 134.6 (C, 
C8a), 134.9 (C, C9a), 138.8 (CH, C7), 140.1 (C, C3”), 140.8 (C, C4a”), 143.6 (C, C2), 151.1 (C, 
C5a”), 156.5 (C, C12”), 163.3 (C, C4), 163.5 (C, C5), 167.1 (C, CONH), 181.8 (C, C9), 193.4 
(C, C10); HRMS (ESI) calcd for (C40H4035ClN3O5 + H+) 678.2729, found 678.2734. Anal. 
(C40H40ClN3O5·HCl·H2O) C, H, N, Cl. 
(±)-N-{9-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]nonyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide [(±)-7e]. 
It was prepared as described for (±)-7a. From rhein, 3 (213 mg, 0.75 mmol), and amine (±)-6e 
(321 mg, 0.75 mmol), a red solid (550 mg) was obtained and purified by column 
chromatography (4060 µm silica gel, hexane/EtOAc/MeOH/Et3N mixtures, gradient elution). 
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On elution with hexane/EtOAc/MeOH/Et3N 20:80:0:0.2 to 0:80:20:0.2, hybrid (±)-7e (118 mg, 
23% yield) was isolated as a red solid; Rf 0.33 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
(±)-7e·HCl: mp 192193 °C (EtOAc/CH2Cl2/MeOH 70:15:15); IR (KBr) ν 35002500 (max 
at 3401, 2925, 2853, O-H, N-H, N+-H and C-H st), 1628, 1584, 1566, 1524 (C=O, ar-C-C and ar-
C-N st) cm1; 1H NMR (500 MHz, CD3OD) δ 1.41 (complex signal, 10H, 3’-H2, 4’-H2, 5’-H2, 
6’H2, 7’-H2), 1.59 (s, 3H, 9”-CH3), superimposed in part 1.64 (m, 2H, 2’-H2), superimposed in 
part 1.66 (tt, J≈J’≈6.0 Hz, 2H, 8’-H2), superimposed 1.84−1.94 (m, 1H, 13”-Hsyn), superimposed 
in part 1.92 (br d,  J=17.0 Hz, 1H, 10”-Hendo), 2.06 (dm, J≈10.5 Hz, 1H, 13”-Hanti), 2.53 (dm, 
J≈17.0 Hz, 1H, 10”-Hexo), 2.76 (m, 1H, 7”-H), superimposed in part 2.79 (br d, J≈18.0 Hz, 1H, 
6”-Hendo), 3.14 (dd, J=18.0 Hz, J’=3.5 Hz, 1H, 6”-Hexo), 3.383.42 (complex signal, 3H, 1’-H2, 
11”-H), 3.86−3.96  (m, 2H, 9’-H2), 4.85 (s, NH, +NH and OH), 5.58 (br d, J=4.0 Hz, 1H, 8”-H), 
7.31 (d, J=8.5 Hz, 1H, 6-H), 7.38 (d, J=8.5 Hz, 1H, 2”-H), 7.57 (s, 1H, 4”-H), 7.63 (s, 1H, 3-H), 
superimposed in part 7.64 (d, J=7.0 Hz, 1H, 8-H), 7.72 (dd, J≈J’≈8.0 Hz, 1H, 7-H), 8.04 (s, 1H, 
1-H), 8.20 (d, J=8.5 Hz, 1H, 1”-H), 8.82 (br s, 1H, CONH); 13C NMR (125.7 MHz, CD3OD) δ 
23.5 (CH3, 9”-CH3), 27.2 (CH, C11”), 27.5 (CH2), 27.6 (CH2) (C6’, C7’), 27.8 (CH, C7”), 29.3 
(CH2, C13”), 29.7 (2CH2), 30.0 (CH2), 30.1 (CH2) (C2’, C3’, C4’, C5’), 31.2 (CH2, C8’), 36.0 
(2CH2, C6”, C10”), 41.0 (CH2, C1’), 49.6 (CH2, C9’), 115.4 (C, C12a”), 116.8 (C, C10a), 117.5 
(C, C11a”), 118.4 (C, C4a), 118.8 (CH, C1), 119.1 (CH, C4”), 120.8 (CH, C8), 123.7 (CH, C3), 
125.1 (CH, C8”), 125.8 (CH, C6), 126.6 (CH, C2”), 129.2 (CH, C1”), 134.6 (2C, C8a, C9”), 
135.1 (C, C9a), 138.7 (CH, C7), 140.2 (C, C3”), 140.8 (C, C4a”), 143.7 (C, C2), 151.0 (C, 
C5a”), 156.6 (C, C12”), 163.4 (C, C4), 163.6 (C, C5), 167.3 (C, CONH), 182.0 (C, C9), 193.5 
(C, C10); HRMS (ESI) calcd for (C41H4235ClN3O5 + H+) 692.2886, found 692.2873. Anal. 
(C41H42ClN3O5·1.3HCl·1.25H2O) C, H, N, Cl. 
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(−)-N-{9-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]nonyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide [(−)-7e]. 
It was prepared as described for (±)-7a. From rhein, 3 (422 mg, 1.49 mmol), and amine (−)-6e 
(632 mg, 1.49 mmol), a red solid (1.10 g) was obtained and purified by column chromatography 
(4060 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient elution). On elution 
with CH2Cl2/MeOH/50% aq. NH4OH 99:1:0.2, hybrid (−)-7e (101 mg, 10% yield) was isolated 
as a red solid; Rf 0.33 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
(−)-7e·HCl: [α]20D=−154 (c=0.10, MeOH); mp 168170 °C (CH2Cl2/MeOH 83:17); IR (KBr) 
ν 35002500 (max at 3226, 3048, 3002, 2925, 2853, 2743, O-H, N-H, N+-H and C-H st), 1766, 
1705, 1675, 1629, 1604, 1582, 1566, 1524, 1509 (C=O, ar-C-C and ar-C-N st) cm1; the 1H 
NMR and 13C NMR spectra were identical to those of ()-7e; HRMS (ESI) calcd for 
(C41H4235ClN3O5 + H+) 692.2886; found 692.2891. Anal. (C41H42ClN3O5·HCl·H2O) C, H, N, Cl. 
(+)-N-{9-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]nonyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide [(+)-7e]. 
It was prepared as described for (±)-7a. From rhein, 3 (477 mg, 1.68 mmol), and amine (+)-6e 
(715 mg, 1.68 mmol), a red solid (1.50 g) was obtained and purified by column chromatography 
(4060 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient elution). On elution 
with CH2Cl2/MeOH/50% aq. NH4OH 99:1:0.2, hybrid (+)-7e (191 mg, 16% yield) was isolated 
as a red solid; Rf 0.33 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
(+)-7e·HCl: [α]20D=+154 (c=0.10, MeOH); mp 164165 °C (CH2Cl2/MeOH 88:12); IR (KBr) 
ν 35002500 (max at 3226, 3049, 2926, 2852, O-H, N-H, N+-H and C-H st), 1763, 1739, 1723, 
1710, 1656, 1629, 1583, 1566, 1555, 1537, 1511, 1501 (C=O, ar-C-C and ar-C-N st) cm1; the 
1H NMR and 13C NMR spectra were identical to those of ()-7e; HRMS (ESI) calcd for 
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(C41H4235ClN3O5 + H+) 692.2886, found 692.2877. Anal. (C41H42ClN3O5·1.25HCl·0.75H2O) C, 
H, N, Cl. 
(±)-N-{10-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-
12-yl)amino]decyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide [(±)-
7f]. It was prepared as described for (±)-7a. From rhein, 3 (344 mg, 1.21 mmol), and amine (±)-
6f (530 mg, 1.21 mmol), a red solid (900 mg) was obtained and purified by column 
chromatography (4060 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient 
elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH 99:1:0.2, hybrid (±)-7f (115 mg, 13% 
yield) was isolated as a red solid; Rf 0.53 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
(±)-7f·HCl: mp 171173 °C (EtOAc/CH2Cl2/MeOH 72:14:14); IR (KBr) ν 35002500 (max at 
3229, 3049, 3002, 2925, 2852, O-H, N-H, N+-H and C-H st), 1767, 1739, 1715, 1675, 1629, 
1604, 1583, 1567, 1524 (C=O, ar-C-C and ar-C-N st) cm1; 1H NMR (500 MHz, CD3OD) δ 
1.34−1.44 (complex signal, 12H, 3’-H2, 4’-H2, 5’-H2, 6’H2, 7’-H2, 8’-H2), 1.58 (s, 3H, 9”-CH3), 
1.66 (tt, J≈J’≈7.0 Hz , 2H, 2’-H2), 1.83 (tt, J≈J’≈7.0 Hz, 2H, 9’-H2), superimposed 1.90−1.93 
(m, 1H, 13”-Hsyn), superimposed in part 1.92 (br d,  J=17.0 Hz, 1H, 10”-Hendo), 2.06 (dm, J≈12.0 
Hz, 1H, 13”-Hanti), 2.52 (br dd, J≈17.0 Hz, J’≈ 4.3 Hz, 1H, 10”-Hexo), 2.75 (m, 1H, 7”-H), 2.82 
(br d, J=18.0 Hz, 1H, 6”-Hendo), 3.15 (dd, J≈18.0 Hz, J’=5.3 Hz, 1H, 6”-Hexo), 3.383.45 
(complex signal, 3H, 1’-H2, 11”-H), 3.87 (dt, J≈J’≈6.5 Hz,  2H, 10’-H2), 4.85 (s, NH, +NH and 
OH), 5.57 (br d, J=5.5 Hz, 1H, 8”-H), 7.27 (dd, J=8.5 Hz, J’=1.0 Hz, 1H, 6-H), 7.39 (dd, J=9.5 
Hz, J’=1.5 Hz, 1H, 2”-H), superimposed in part 7.59 (s, 1H, 4”-H), 7.60 (d, J=1.5 Hz, 1H, 3-H), 
7.63 (dd, J=7.5 Hz, J’=1.0 Hz, 1H, 8-H), 7.70 (dd, J≈J’≈8.0 Hz, 1H, 7-H), 8.01 (d, J=1.5 Hz, 
1H, 1-H), 8.21 (d, J=9.5 Hz, 1H, 1”-H); 13C NMR (125.7 MHz, CD3OD) δ 23.5 (CH3, 9”-CH3), 
27.2 (CH, C11”), 27.7 (2CH2), 27.8 (CH + CH2) (C6’, C7’, C8’, C7”), 29.3 (CH2, C13”), 30.03 
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(CH2), 30.05 (CH2), 30.22 (CH2), 30.25 (CH2) (C2’, C3’, C4’, C5’), 31.2 (CH2, C9’), 36.0 
(2CH2, C6”, C10”), 41.1 (CH2, C1’), 49.6 (CH2, C10’), 115.5 (C, C12a”), 116.8 (C, C10a), 117.5 
(C, C11a”), 118.4 (C, C4a), 118.9 (CH, C1), 119.1 (CH, C4”), 120.9 (CH, C8), 123.7 (CH, C3), 
125.1 (CH, C8”), 125.8 (CH, C6), 126.7 (CH, C2”), 129.3 (CH, C1”), 134.6 (2C, C8a, C9”), 
135.0 (C, C9a), 138.7 (CH, C7), 140.2 (C, C3”), 140.8 (C, C4a”), 143.7 (C, C2), 151.0 (C, 
C5a”), 156.6 (C, C12”), 163.3 (C, C4), 163.6 (C, C5), 167.2 (C, CONH), 181.9 (C, C9), 193.5 
(C, C10); HRMS (ESI) calcd for (C42H4435ClN3O5 + H+) 706.3042, found 706.3038. Anal. 
(C42H44ClN3O5·HCl·0.5H2O) C, H, N, Cl. 
(±)-N-{11-[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-
12-yl)amino]undecyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxamide 
[(±)-7g]. It was prepared as described for (±)-7a. From rhein, 3 (491 mg, 1.73 mmol), and amine 
(±)-6g (785 mg, 1.73 mmol), a red solid (1.60 g) was obtained and purified by column 
chromatography (4060 µm silica gel, CH2Cl2/MeOH/50% aq. NH4OH mixtures, gradient 
elution). On elution with CH2Cl2/MeOH/50% aq. NH4OH 99:1:0.2, hybrid (±)-7g (338 mg, 27% 
yield) was isolated as a red solid; Rf 0.50 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
(±)-7g·HCl: mp 171172 °C (EtOAc/CH2Cl2/MeOH 60:20:20); IR (KBr) ν 35002500 (max 
at 3226, 3048, 3007, 2924, 2852, 2645, O-H, N-H, N+-H and C-H st), 1765, 1675, 1628, 1607, 
1583, 1567, 1522 (C=O, ar-C-C and ar-C-N st) cm1; 1H NMR (500 MHz, CD3OD) δ 1.33−1.43 
(complex signal, 14H, 3’-H2, 4’-H2, 5’-H2, 6’H2, 7’-H2, 8’-H2, 9’-H2), 1.58 (s, 3H, 9”-CH3), 1.66 
(tt, J≈J’≈7.0 Hz, 2H, 2’-H2), 1.82 (tt, J≈J’≈17.0 Hz, 2H, 10’-H2), superimposed 1.89−1.93 (m, 
1H, 13”-Hsyn), superimposed in part 1.91 (br d,  J=17.0 Hz, 1H, 10”-Hendo), 2.05 (dm, J≈10.5 Hz, 
Hz, 1H, 13”-Hanti), 2.52 (br dd, J≈17.0 Hz, J’≈4.5 Hz, 1H, 10”-Hexo), 2.75 (m, 1H, 7”-H), 2.82 
(br d, J=18.0 Hz, 1H, 6”-Hendo), 3.14 (dd, J≈18.0 Hz, J’=5.5 Hz, 1H, 6”-Hexo), superimposed in 
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part 3.37 (m, 1H, 11”-H), superimposed in part 3.40 (tt, J≈J’≈7.0 Hz, 2H, 1’-H2), 3.86 (dt, 
J≈J’≈7.0 Hz,  2H, 11’-H2), 4.85 (s, NH, +NH and OH), 5.57 (br d, J=5.5 Hz, 1H, 8”-H), 7.23 (dd, 
J=8.5 Hz, J’=1.0 Hz, 1H, 6-H), 7.37 (dd, J=9.0 Hz, J’≈1.5 Hz, 1H, 2”-H), superimposed in part 
7.57 (d, J=1.5 Hz, 1H, 4”-H), superimposed in part 7.58 (d, J=2.0 Hz, 1H, 3-H), superimposed in 
part 7.58 (dd, J=8.0 Hz, J’=1.0 Hz, 1H, 8-H), 7.67 (dd, J≈J’≈8.0 Hz, 1H, 7-H), 7.97 (d, J=1.5 
Hz, 1H, 1-H), 8.20 (d, J=9.0 Hz, 1H, 1”-H); 13C NMR (125.7 MHz, CD3OD) δ 23.5 (CH3, 9”-
CH3), 27.2 (CH, C11”), 27.7 (CH2), 27.82 (CH, C7”), 27.83 (2CH2) (C7’, C8’, C9’, C7”), 29.3 
(CH2, C13”), 30.1 (2CH2), 30.2 (CH2), 30.36 (CH2), 30.40 (CH2) (C2’, C3’, C4’, C5’, C6’), 31.2 
(CH2, C10’), 36.0 (2CH2, C6”, C10”), 41.2 (CH2, C1’), 49.6 (CH2, C11’), 115.4 (C, C12a”), 
116.7 (C, C10a), 117.5 (C, C11a”), 118.3 (C, C4a), 118.9 (CH, C1), 119.1 (CH, C4”), 120.8 
(CH, C8), 123.7 (CH, C3), 125.1 (CH, C8”), 125.8 (CH, C6), 126.6 (CH, C2”), 129.3 (CH, C1”), 
134.5 (C, C9”), 134.6 (C, C8a), 134.9 (C, C9a), 138.7 (CH, C7), 140.2 (C, C3”), 140.8 (C, 
C4a”), 143.7 (C, C2), 151.0 (C, C5a”), 156.6 (C, C12”), 163.3 (C, C4), 163.5 (C, C5), 167.1 (C, 
CONH), 181.8 (C, C9), 193.4 (C, C10); HRMS (ESI) calcd for (C43H4635ClN3O5 + H+) 720.3199, 
found 720.3195. Anal. (C43H46ClN3O5·HCl·0.5H2O) C, H, N, Cl. 
(±)-N-{4-{[(3-Chloro-6,7,10,11-tetrahydro-9-methyl-7,11-methanocycloocta[b]quinolin-
12-yl)amino]methyl}benzyl}-9,10-dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-
carboxamide [(±)-7h]. It was prepared as described for (±)-7a. From rhein, 3 (548 mg, 1.93 
mmol), and amine (±)-6h (780 mg, 1.93 mmol), a red solid (1.07 g) was obtained and purified by 
column chromatography (4060 µm silica gel, hexane/EtOAc/Et3N mixtures, gradient elution). 
On elution with hexane/EtOAc/Et3N 40:60:0.2, hybrid (±)-7h (113 mg, 9% yield) was isolated as 
a red solid; Rf 0.57 (CH2Cl2/MeOH/50% aq. NH4OH 9:1:0.05). 
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(±)-7h·HCl: mp 129130 °C (EtOAc/CH2Cl2/MeOH 66:17:17); IR (KBr) ν 35002500 (max 
at 3245, 3055, 2925, 2852, 2790, O-H, N-H, N+-H and C-H st), 1705, 1673, 1629, 1607, 1583, 
1560, 1516 (C=O, ar-C-C and ar-C-N st) cm1; 1H NMR (400 MHz, CD3OD) δ 1.59 (s, 3H, 9”-
CH3), superimposed 1.92–1.98 (m, 1H, 13”-Hsyn), 1.97 (br d, J=16.8 Hz, 1H, 10”-Hendo), 2.08 
(dm, J=12.4 Hz, 1H, 13”-Hanti), 2.53 (br dd, J≈16.8 Hz, J’≈5.0 Hz, 1H, 10”-Hexo), 2.78 (m, 1H, 
7”-H), 2.86 (br d, J=18.0 Hz, 1H, 6”-Hendo), 3.20 (dd, J≈18.0 Hz, J’=5.6 Hz, 1H, 6”-Hexo), 3.47 
(m, 1H, 11”-H), 4.60 (s, 2H, CH2NH), 4.85 (s, NH, +NH and OH), 5.18 (s, 2H, CH2NHCO), 5.59 
(m, 1H, 8”-H), 7.28 (dd, J=9.2 Hz, J’=2.0 Hz, 1H, 2”-H), 7.34 (dd, J=8.0 Hz, J’=2.0 Hz, 1H, 6-
H), 7.41 (d, J=8.4 Hz, 2H) and 7.47 (d, J=8.4 Hz, 2H) [2’(6’)-H2, 3’(5’)-H2], 7.67 (d, J=2.0 Hz, 
1H) and 7.69 (d, J=2.0 Hz, 1H) (3-H, 4”-H), 7.76 (dd, J≈J’≈7.2 Hz, 1H, 7-H), 7.79 (dd, J=7.2 
Hz, J’=2.0 Hz, 1H, 8-H), 8.15 (d, J≈2.0 Hz, 1H, 1-H), 8.21 (d, J=9.2 Hz, 1H, 1”-H); 13C NMR 
(125.7 MHz, CD3OD) δ 23.5 (CH3, 9”-CH3), 27.5 (CH, C11”), 27.8 (CH, C7”), 29.3 (CH2, 
C13”), 36.0 (CH2, C6”), 36.2 (CH2, C10”), 44.3 (CH2, CH2NH), 51.9 (CH2, CH2NHCO), 115.4 
(C, C12a”), 116.9 (C, C10a), 118.2 (C, C11a”), 118.5 (C, C4a), 118.8 (CH, C1), 119.0 (CH, 
C4”), 120.9 (CH, C8), 123.7 (CH, C3), 125.0 (CH, C8”), 125.8 (CH, C6), 126.6 (CH, C2”), 
128.1 (CH), 129.8 (CH) [C2’(6’), C3’(5’)], 129.3 (CH, C1”), 134.6 (C, C9”), 134.7 (C, C8a), 
135.0 (C, C9a), 137.8 (C) and 139.2 (C) (C1’, C4’), 138.8 (CH, C7), 140.2 (C, C3”), 140.7 (C, 
C4a”), 143.1 (C, C2), 151.6 (C, C5a”), 157.1 (C, C12”), 163.3 (C, C4), 163.6 (C, C5), 167.1 (C, 
CONH), 182.0 (C, C9), 193.5 (C, C10); HRMS (ESI) calcd for (C40H3235ClN3O5 + H+) 670.2103, 
found 670.2104. Anal. (C40H32ClN3O5·1.1HCl·1.4H2O) C, H, N, Cl. 
In Vitro Biological Studies. AChE and BChE Inhibition Assay. Human recombinant AChE 
(Sigma, Milan, Italy) inhibitory activity was evaluated spectrophotometrically by the method of 
Ellman et al.46 Initial rate assays were performed at 37 ºC with a Jasco V-530 double beam 
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spectrophotometer. Stock solutions of the tested compounds (1 mM) were prepared in MeOH 
and diluted in MeOH. The assay solution consisted of a 0.1 M potassium phosphate buffer, pH 
8.0, with the addition of 340 μM 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB, used to produce the 
yellow anion of 5-thio-2-nitrobenzoic acid), 0.02 unit/mL hAChE and 550 μM substrate 
(acetylthiocholine iodide). Assay solutions with and without inhibitor were preincubated at 37 ºC 
for 20 min followed by the addition of substrate. Blank solutions containing all components 
except hAChE were prepared in parallel to account for the non-enzymatic hydrolysis of the 
substrate. Five increasing concentrations of the inhibitor were used, able to give an inhibition of 
the enzymatic activity in the range of 20–80%. The results were plotted by placing the 
percentage of inhibition in function of the decimal log of the final inhibitor concentration. Linear 
regression and IC50 values were calculated using Microcal Origin 3.5 software (Microcal 
Software, Inc). 
Human serum BChE inhibitory activities were also evaluated spectrophotometrically by the 
method of Ellman et al.46 The reactions took place in a final volume of 300 μL of 0.1 M 
phosphate-buffered solution pH 8.0, containing hBChE (0.02 u/mL) and 333 μM DTNB 
solution. Inhibition curves were performed in duplicates using at least 10 increasing 
concentrations of inhibitor and preincubated for 20 min at 37 ºC. One duplicate sample without 
inhibitor was always present to yield 100% of BChE activity. Then substrate butyrylthiocholine 
iodide (300 μM, Sigma-Aldrich) was added and the reaction was developed for 5 min at 37 ºC. 
The color production was measured at 414 nm using a labsystems Multiskan spectrophotometer. 
Data from concentrationinhibition experiments of the inhibitors were calculated by non-linear 
regression analysis, using the GraphPad Prism program package (GraphPad Software; San 
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Diego, USA), which gave estimates of the IC50 values. Results are expressed as mean  S.E.M. 
of at least 4 experiments performed in duplicate. 
Kinetic Analysis of AChE Inhibition. To assess the mechanism of action of hybrid (–)-7e, 
reciprocal plots of 1/velocity versus 1/[Substrate] were constructed at relatively low 
concentration of substrate (0.5620.112 mM) by using Ellman’s method46 and human 
recombinant AChE (Sigma, Milan, Italy). Three concentrations of inhibitor were selected for this 
study: 0.84, 1.34, 3.65 nM. The plots were assessed by a weighted least-squares analysis that 
assumed the variance of the velocity (v) to be a constant percentage of v for the entire data set. 
Data analysis was performed with GraphPad Prism 4.03 software (GraphPad Software Inc.). 
Calculation of the inhibitor constant (Ki) value was carried out by re-plotting slopes of lines 
from the Lineweaver-Burk plot versus the inhibitor concentration and Ki was determined as the 
intersect on the negative x-axis. K’i (dissociation constant for the enzyme–substrate–inhibitor 
complex) value was determined by plotting the apparent 1/vmax versus inhibitor concentration.87 
AChE-Induced Aβ40 Aggregation Inhibition Assay.49 Thioflavin T(Basic Yellow 1), 
human recombinant AChE lyophilized powder, and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) 
were purchased from Sigma Chemicals. Buffers and other chemicals were of analytical grade. 
Absolute DMSO over molecular sieves was from Fluka. Water was deionised and doubly 
distilled. Aβ40, supplied as trifluoroacetate salt, was purchased from Bachem AG (Germany). 
Aβ40 (2 mg mL–1) was dissolved in HFIP, lyophilized and then resolubilized in DMSO to get a 
2.3 mM Aβ40 solution. 1 mM solutions of tested inhibitors were prepared by dissolution in 
MeOH. 
Aliquots of2 μL Aβ40 peptide were incubated for 24 h at room temperature in 0.215 M 
sodium phosphate buffer (pH 8.0) at a final concentration of 230μM. For co-incubation 
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experiments aliquots (16 μL) of hAChE (final concentration 2.30 μM, Aβ/AChE molar ratio 
100:1) and AChE in the presence of 2 μL of the tested inhibitor (final inhibitor concentration 100 
μM) in 0.215 M sodium phosphate buffer pH 8.0 solution were added. Blanks containing Aβ40  
alone, human recombinant AChE alone, and Aβ40 plus tested inhibitors in 0.215 M sodium 
phosphate buffer (pH 8.0) were prepared. The final volume of each vial was 20 μL. Each assay 
was run in duplicate. To quantify amyloid fibril formation, the thioflavin T fluorescence method 
was then applied.88 The fluorescence intensities due to β-sheet conformation were monitored for 
300 s at em=490 nm (exc=446 nm). The percent inhibition of the AChE-induced aggregation 
due to the presence of the tested compound was calculated by the following expression: 100  
(IFi/IFo × 100) where IFi and IFo are the fluorescence intensities obtained for Aβ  plus AChE in 
the presence and in the absence of inhibitor, respectively, minus the fluorescence intensities due 
to the respective blanks. 
Aβ42 Self-Aggregation Inhibition Assay. As reported in a previously published protocol,58  
HFIP pretreated Aβ42 samples (Bachem AG, Switzerland) were first solubilized with a 
CH3CN/0.3 mM Na2CO3/250 mM NaOH (48.4:48.4:3.2) mixture to obtain a 500 μM solution. 
Experiments were performed by incubating the peptide in 10 mM phosphate buffer (pH = 8.0) 
containing 10 mM NaCl, at 30 °C for 24 h (final Aβ concentration 50 μM) with and without 
inhibitor (10 μM, Aβ/inhibitor = 5/1). Blanks containing the tested inhibitors were also prepared 
and tested. To quantify amyloid fibrils formation, the thioflavin T fluorescence method was 
used.88 After incubation, samples were diluted to a final volume of 2.0 mL with 50 mM 
glycineNaOH buffer (pH 8.5) containing 1.5 μM thioflavin T. A 300-second-time scan of 
fluorescence intensity was carried out (λexc=446 nm; λem=490 nm, FP-6200 fluorometer, Jasco 
Europe), and values at plateau were averaged after subtracting the background fluorescence of 
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1.5 μM thioflavin T solution. The fluorescence intensities were compared and the percent 
inhibition due to the presence of the inhibitor was calculated by the following formula: 100  
(IFi/IFo  100) where IFi and IFo are the fluorescence intensities obtained for Aβ42 in the 
presence and in the absence of inhibitor, respectively. 
BACE-1 Inhibition Assay. β-Secretase (BACE-1, Sigma) inhibition studies were performed 
by employing a peptide mimicking APP sequence as substrate (Methoxycoumarin-Ser-Glu-Val-
Asn-Leu-Asp-Ala-Glu-Phe-Lys-dinitrophenyl, M-2420, Bachem, Germany). The following 
procedure was employed: 5 μL of test compounds (or DMSO, if preparing a control well) were 
pre-incubated with 175 μL of enzyme (in 20 mM sodium acetate pH 4.5 containing CHAPS 
0.1% w/v) for 1 h at room temperature. The substrate (3 μM, final concentration) was then added 
and left to react for 15 min. The fluorescence signal was read at λem=405 nm (λexc=320 nm). The 
DMSO concentration in the final mixture was maintained below 5% (v/v) to guarantee no 
significant loss of enzyme activity. The fluorescence intensities with and without inhibitor were 
compared and the percent inhibition due to the presence of test compounds was calculated. The 
background signal was measured in control wells containing all the reagents, except BACE-1 
and subtracted. The % inhibition due to the presence of increasing test compound concentration 
was calculated by the following expression: 100 – (IFi/IFo  100) where IFi and IFo are the 
fluorescence intensities obtained for BACE-1 in the presence and in the absence of inhibitor, 
respectively. Inhibition curves were obtained by plotting the % inhibition versus the logarithm of 
inhibitor concentration in the assay sample, when possible. The linear regression parameters 
were determined and the IC50 extrapolated (GraphPad Prism 4.0, GraphPad Software Inc.). To 
demonstrate inhibition of BACE-1 activity a peptido-mimetic inhibitor (β-secretase inhibitor IV, 
Calbiochem) was serially diluted into the reactions’ wells (IC50 = 13.0 ± 0.1 nM). 
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BBB Permeation Assay. The brain penetration of the synthesized hybrids was assessed using 
the parallel artificial membrane permeation assay for blood-brain barrier described by Di et al.71 
The in vitro permeability (Pe) of fourteen commercial drugs through lipid extract of porcine 
brain membrane together with that of the test compounds was determined. Commercial drugs 
and synthesized hybrids were tested using a mixture of PBS/EtOH 70:30. Assay validation was 
made by comparing the experimental permeability of the different compounds with the literature 
values of the commercial drugs, which showed a good correlation: Pe (exp) = 1.4525 Pe (lit)  
0.4926 (R2 = 0.9199). From this equation and taking into account the limits established by Di et 
al. for BBB permeation, we established the following ranges of permeability: compounds of high 
BBB permeation  (CNS+): Pe (106 cm s1) > 5.3; compounds of low BBB permeation (CNS): 
Pe (106 cm s1) < 2.4, and  compounds of uncertain BBB permeation (CNS+/): 5.3 > Pe (106 
cm s1) > 2.4. 
Aβ42 Aggregation Inhibition Assay in Intact Escherichia coli Cells Overexpressing Aβ42 
and Tau. Cloning and overexpression of Aβ42 peptide: Escherichia coli competent cells BL21 
(DE3) were transformed with the pET28a vector (Novagen, Inc., Madison, WI, USA) carrying 
the DNA sequence of Aβ42. Because of the addition of the initiation codon ATG in front of both 
genes, the overexpressed peptide contains an additional methionine residue at its N terminus. For 
overnight culture preparation, 10 mL of lysogeny broth (LB) medium containing 50 μg·mL–1 of 
kanamycin were inoculated with a colony of BL21 (DE3) bearing the plasmid to be expressed at 
37 °C. After overnight growth, the OD600 was usually 2–2.5. For expression of Aβ42 peptide, 
20 μL of overnight culture were transferred into eppendorf tubes of 1.5 mL containing 980 μL of 
LB medium with 50 μg·mL–1 of kanamycin, 1 mM of isopropyl 1-thio-β-D-galactopyranoside 
(IPTG) and 10 μM of each hybrid 7 or reference compound to be tested in DMSO. The samples 
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were grown for 24 h at 37 °C and 1400 rpm using a Thermomixer (Eppendorf, Hamburg, 
Germany). In the negative control (without drug) the same amount of DMSO was added in the 
sample. 
Cloning and overexpression of tau protein: E. coli BL21 (DE3) competent cells were 
transformed with pTARA containing the RNA-polymerase gen of T7 phage (T7RP) under the 
control of the promoter PBAD. E. coli BL21 (DE3) with pTARA competent cells were 
transformed with pRKT42 vector encoding four repeats of tau protein in two inserts. For 
overnight culture preparation, 10 mL of M9 medium containing 0.5% of glucose, 50 μg·mL–1 of 
ampicillin and 12.5 μg·mL–1 of chloramphenicol were inoculated with a colony of BL21 (DE3) 
bearing the plasmids to be expressed at 37 °C. After overnight growth, the OD600 was usually 
2–2.5. For expression of tau protein, 20 μL of overnight culture were transferred into eppendorf 
tubes of 1.5 mL containing 980 μL of M9 medium containing 0.25% of arabinose, 0.5% of 
glucose, 50 μg·mL–1 of ampicillin and 12.5 μg·mL–1 of chloramphenicol and 10 μM of each 
hybrid 7 or reference compound to be tested in DMSO. The samples were grown for 24 h at 37 
°C and 1400 rpm using a Thermomixer (Eppendorf, Hamburg, Germany). In the negative control 
(without drug) the same amount of DMSO was added in the sample. 
Thioflavin-S (Th-S) steady-state fluorescence: Th-S (T1892) and other chemical reagents were 
purchased from Sigma (St. Louis, MO). Th-S stock solution (250 mM) was prepared in double-
distilled water purified through a Milli-Q system (Millipore, USA). Fluorescent spectral scans of 
Th-S were analyzed using an Aminco Bowman Series 2 luminescence spectrophotometer 
(Aminco-Bowman AB2, SLM Aminco, Rochester, NY, USA). For the fluorescence assay, 25 
μM of Th-S (20 μL of Th-S in 180 μL of sample) were added to samples and spectra were 
recorded after 15 min equilibration at 37 ºC. Excitation and emission slit widths of 5 nm were 
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used. Finally, the fluorescence emission at 520 nm, when exciting at 440 nm, was recorded. In 
order to normalize the Th-S fluorescence as a function of the bacterial concentration, OD600 was 
obtained using a Shimadzu UV-2401 PC UV–Vis spectrophotometer (Shimadzu, Japan). Note 
that the fluorescence normalization has been carried out considering as 100% the Th-S 
fluorescence of the bacterial cells expressing the peptide or protein in the absence of drug and 
0% the Th-S fluorescence of the bacterial cells non-expressing the peptide or protein. 
Ex Vivo Studies in C57bl6 Mice. Electrophysiological Assays in Hippocampal Slices 
Incubated with Aβ Oligomers. Hippocampal slices were prepared according to standard 
procedures previously described.89,90 Briefly, transverse slices (350 μm) from the dorsal 
hippocampus were cut under cold artificial cerebrospinal fluid (ACSF, in mM: 124 NaCl, 2.6 
NaHCO3, 10 D-glucose, 2.69 KCl, 1.25 KH2PO4 2.5 CaCl2, 1.3 MgSO4, and 2.60 NaHPO4) 
using a Vibratome (Leica VT 1000s, Germany) and incubated in ACSF for 1 h at room 
temperature. In all experiments, 10 μM picrotoxin (PTX) was added to suppress inhibitory 
GABAA transmission. Slices were transferred to an experimental chamber (2 mL), superfused (3 
mL/min, at 20–22 ºC) with gassed ACSF and visualized by trans-illumination with a binocular 
microscope (MSZ-10, Nikon, Melville, NY). To evoke field excitatory postsynaptic potentials 
(fEPSPs), we stimulated with bipolar concentric electrodes (Platinum/Iridium, 125 µm OD 
diameter, FHC Inc., Bowdoin, ME) generated by a stimulator (Axon 700b, Molecular Devices, 
Sunnyvale, CA) and connected to an isolation unit (Isoflex, AMPI, Jerusalem, Israel). The 
stimulation was in the Stratum Radiatum within 100-200 μm from the recording site. The paired 
pulse facilitation index was calculated by ((R2–R1)/R1), where R1 and R2 were the peak 
amplitudes of the first and second fEPSP respectively. To generate LTP we used Theta Burst 
Stimulation (TBS) consisting of 5 trains of stimulus with an inter-train interval of 20 s. Each 
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train consisted of 10 bursts at 5 Hz and each burst having 4 pulses at 100 Hz. To generate LTD 
we used Low Frequency Stimulation (LFS) consisting in 900 paired pulses at 1 Hz. Recordings 
were filtered at 2.0-3.0 kHz, sampled at 4.0 kHz using an A/D converter, and stored with pClamp 
10 (Molecular Devices). Evoked postsynaptic responses were analyzed off-line, using an 
analysis software (pClampfit, Molecular Devices), which allowed visual detection of events, 
computing only those events that exceeded an arbitrary threshold. 
Determination of Synaptic Protein Levels in Hippocampal Slices Incubated with Aβ 
Oligomers. Immunoblotting: The hippocampus of C57bl6 mice were dissected on ice and 
immediately frozen at –150 ºC or processed. Briefly, hippocampal tissue was homogenized in 
RIPA buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
and 1% SDS) supplemented with a protease inhibitor cocktail (Sigma-Aldrich P8340) and 
phosphatase inhibitors (50 mM NaF, 1 mM Na3VO4 and 30 μM Na4P2O7) using a Potter 
homogenizator and then passed sequentially through different caliber syringes. Protein samples 
were centrifuged at 14000 rpm at 4 ºC twice for 10 min. Protein concentration was determined 
using the BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL). 20 and 40 μg of 
hippocampal samples were resolved by 10% SDS-PAGE, transferred to a PVDF membrane. The 
reactions were followed by incubation with primary antibodies, secondary antibodies anti-mouse, 
anti-goat or anti-rabbit IgG peroxidase conjugated (Pierce) and developed using an ECL kit 
(Western Lightning Plus ECL, PerkinElmer). 
In Vivo Studies in APP-PS1 Mice. 
Animals and Treatment. APPswe/PSEN1ΔE9 (APP-PS1) mice, which express the Swedish 
mutation of APP (K595N/M596L) and PS1 with the deletion of exon 9 were obtained from The 
Jackson Laboratory (Bar Harbor, ME; mice stock #004462). All animals were housed in 
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temperature- and light-controlled rooms, with food and water ad libitum during the treatment. 
Six and ten month-old mice were treated and handled according to the National Institutes of 
Health guidelines (NIH, Baltimore, MD). Treatments were performed by intra-peritoneal (i.p.) 
injection of 2.0 mg/kg enantiopure rhein–huprine hybrids (+)-7e or (–)-7e with saline solution as 
vehicle, three times per week during 4 weeks. Transgenic control animals were injected only 
with the vehicle. 
Immunoblotting. The hippocampus from control or treated APP-PS1 mice were dissected on 
ice and immediately frozen at –150 ºC or processed has detailed previously.90,91 Briefly, 
hippocampus were homogenized in RIPA buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, and 1% SDS) supplemented with a protease inhibitor 
cocktail (Sigma-Aldrich P8340) and phosphatase inhibitors (50 mM NaF, 1 mM Na3VO4 and 30 
μM Na4P2O7) using a Potter homogenizator and then passed sequentially through different 
caliber syringes. Protein samples were centrifuged at 14000 rpm at 4 ºC twice for 20 min. Protein 
concentration was determined using the BCA Protein Assay Kit (Pierce Biotechnology, 
Rockford, IL). 
Aβ detection. For the detection of soluble Aβ peptides, samples from hippocampus were 
centrifugated to 20.000g for 1 h and the protein concentration from supernatant was determined 
using the BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL).  80 μg of proteins were 
resolved in 17.5% SDS polyacrylamide Tris-tricine gels, followed by immunoblotting on PVDF 
membranes using mouse anti-Aβ protein 6E10 (Covance). To analyze the levels of APP the 
antibody MAB348 (Millipore) was utilized. Band intensities were visualized by ECL kit 
(Western Lightning Plus ECL, PerkinElmer), scanned and densitometrically quantified using 
ImageJ software.85,92 
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Docking in AChE. AChE models were built up from the human recombinant AChE structure 
3LII.93 The structure was refined by addition of missing hydrogen atoms, removal of non-
standard residues and generation of disulfide bonds Cys69–Cys96, Cys257–272 and Cys405–
Cys524. Since the fragment between residues Gly264 and Pro258 is not observed in the X-ray 
structure, it was modeled from the equivalent fragment of Torpedo californica AChE (TcAChE).  
Finally, the enzyme was modeled in its physiological active form with neutral His447 and 
neutral Glu334, which together with Ser203 forms the catalytic triad. We considered the standard 
ionization state at phisiological pH for the rest of ionizable residues with exception of Glu450, 
which was modeled in its neutral state.  
The binding mode of (–)-7h and (+)-7h to AChE was explored by means of docking 
calculations performed with rDock, whose reliability in predicting binding mode for dual site 
inhibitors of AChE has been largely demonstrated in previous studies.94 The orientation of 
Tyr337 residue was modified to mimic the conformation of the equivalent residue Phe330 in the 
complex between TcAChE and (–)-huprine X (PDB 1E66).39 To explore the binding at the PAS, 
three different AChE models differing in the orientation of Trp286 were built. The side chain of 
Trp286 was oriented following the three orientations found in X-ray structures deposited in the 
Protein Data Bank, which can be characterized by dihedral angles 1 (NCCC) and 2 
(CCCC2) close to i) 60 and 80, ii) 120 and +50, and iii) 160 and 120 degrees. PDB 
structures 1N5R (AChE–propidium complex), 2CKM (AChE–bis(7)-tacrine complex) and 1Q83 
(AChE–syn-TZ2PA6 complex), respectively, are representative cases of these orientations and 
were used to generate the corresponding models. The docking volume was defined as the space 
covered by the catalytic, midgorge and peripheral sites and each compound was subjected to 100 
docking runs and solutions clustered according to the RMSD among its heavy atoms using a 
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threshold of 2.0 Å, selecting the best ranked pose to be representative of the cluster. The 
resulting binding modes were analyzed by visual inspection in conjunction with the docking 
scores. 
Docking and molecular dynamics in BACE-1. In order to explore the binding mode of 
rhein–huprine hybrids, druggable pockets were identified using the MDpocket program.95 
Calculations were performed for X-ray structures 1M4H, 1SGZ, 2OHL and 3CIB chosen to 
account for structural variability in the flexible ‘flap’ loop located over the catalytic site and of 
certain regions (loops 9–12 and 263–268) and side chains in the peptide binding groove. The 
structures were refined by addition of missing hydrogen atoms, removal of non-standard residues 
and generation of disulfide bonds Cys155–Cys359, Cys217–Cys382 and Cys269–Cys319. Only 
druggable pockets that shared α-spheres in at least three different structures were retained and 
ranked according to druggability criteria.96 
GLIDE97 was used to explore the preferred binding sites of the huprine and 
hydroxyanthraquinone moieties (obtained by replacing the methylene chain by a methyl group) 
to the druggable sites and to explore the binding mode of compound 7h. The docking cavity was 
defined as a 13824Å3 cube whose center was located among residues Gly13, Leu30, Tyr71, 
Ile110, Trp115 and Gly230. Three different protonation states were considered for the catalytic 
diad (Asp32, Asp228), including the doubly deprotonated form and the two single deprotonated 
forms. Default settings were used and the best poses were clustered according to the RMSD 
between its heavy atoms, with a threshold of 2.0 Å and subsequently evaluated using the Glide-
XP scoring function. 
The binding modes proposed for (–)-7h and (+)-7h were assessed by means of Molecular 
Dynamics (MD) using GPU-accelerated PMEMD98 module from the AMBER12 software 
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package.99 The Parm99SB100 force field was used for the protein and the gaff force field101 was 
used to assign parameters to both ligands. Na+ cations added to neutralize the system were 
treated according with Joung and Cheatham parameters.102 The ligands charge distribution were 
determined from a fit to the HF/6-31G(d) electrostatic potential obtained with Gaussian09103 
using the RESP104 protocol as implemented in the Antechamber module of AmberTools12 
software package.   
Each system comprised around 46000 atoms, including the protein–ligand complex and 8 Na+ 
cations solvated on a truncated octahedral box of 13000 TIP3P water molecules.105 The geometry 
of the system was minimized in four steps. First, water molecules were refined though 4500 
steepest descent algorithm followed by 10500 steps of conjugate gradient. Then, protein and 
ligand hydrogen atoms positions were optimized using 500 steps of steepest descent and 4500 of 
conjugate gradient. Next the ligand, water molecules and counterions were further optimized 
with 2000 steps of steepest descent and 6000 of conjugate gradient and, at the last step, the 
whole system was optimized with 2500 steps of steepest descent and 4500 of conjugate gradient. 
At this point, 5 different replicas for each ligand were generated by randomly assigning different 
sets of velocities to the initial coordinates, all fitting a Maxwell distribution for a temperature of 
50K. For each one of the replicas, thermalization was performed in the canonical ensemble 
during five 25 ps steps, using a time step of 1 fs and increasing the temperature from 50 to 298 
K. Concomitantly, the inhibitor and the residues in the binding site were restrained during 
thermalization using a variable restraint force that was decreased sequentially from 5 kcal mol–1 
Å–2 to 0 kcal mol–1 Å–2 using increments of 1 kcal mol–1 Å–2 within the different thermalization 
stages. Prior to the production runs, a short 1 ns simulation in the isothermal-isobaric ensemble 
was performed in other to reach a stable density value of 1003 kg m–3. Production runs consisted 
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of 50 ns trajectories (accounting for a global simulation time of 200 ns per ligand) using SHAKE 
for bonds involving hydrogen atoms, allowing for a timestep of 2 fs, in conjunction with periodic 
boundary conditions at constant volume and temperature (298 K; Langevin thermostat with a 
collision frequency of 3 ps–1), particle mesh Ewald for long-range electrostatic interactions, and a 
cutoff of 10 Å for nonbonded interactions. 
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